<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff - Gurusamy, KS - 2018 | Cochrane Library</title> <meta content="Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff - Gurusamy, KS - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012860.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff - Gurusamy, KS - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012860.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012860.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff" name="citation_title"/> <meta content="Kurinchi Selvan Gurusamy" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="k.gurusamy@ucl.ac.uk" name="citation_author_email"/> <meta content="Lawrence MJ Best" name="citation_author"/> <meta content="Royal Free Campus, UCL Medical School" name="citation_author_institution"/> <meta content="Cynthia Tanguay" name="citation_author"/> <meta content="CHU Sainte‐Justine" name="citation_author_institution"/> <meta content="Elaine Lennan" name="citation_author"/> <meta content="University Hospital Southampton" name="citation_author_institution"/> <meta content="Mika Korva" name="citation_author"/> <meta content="Finnish Institute of Occupational Health" name="citation_author_institution"/> <meta content="Jean‐François Bussières" name="citation_author"/> <meta content="CHU Sainte‐Justine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012860.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/03/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012860.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012860.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012860.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Hazardous Substances [analysis, urine]; *Nursing Staff, Hospital; *Pharmacists; *Pharmacy Technicians; Antineoplastic Agents [analysis, urine]; Chemical Safety [*instrumentation, *methods]; Cyclophosphamide [analysis, urine]; Deoxycytidine [analogs &amp; derivatives, analysis, urine]; Endocrine Disruptors [analysis, urine]; Fluorouracil [analysis, urine]; Ifosfamide [analysis, urine]; Observational Studies as Topic; Occupational Exposure [*prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012860.pub2&amp;doi=10.1002/14651858.CD012860.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012860\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012860\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012860.pub2",title:"Closed\\u2010system drug\\u2010transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff",firstPublishedDate:"Mar 27, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Work Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012860.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012860.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012860.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012860.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012860.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012860.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012860.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012860.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012860.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012860.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6363 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012860.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/appendices#CD012860-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/table_n/CD012860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/table_n/CD012860StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Closed‐system drug‐transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kurinchi Selvan Gurusamy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0003">Lawrence MJ Best</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0004">Cynthia Tanguay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0005">Elaine Lennan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0006">Mika Korva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information#CD012860-cr-0007">Jean‐François Bussières</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information/en#CD012860-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 March 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012860.pub2">https://doi.org/10.1002/14651858.CD012860.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012860-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012860-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012860-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012860-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012860-abs-0001" lang="en"> <section id="CD012860-sec-0001"> <h3 class="title" id="CD012860-sec-0001">Background</h3> <p>Occupational exposure to hazardous drugs can decrease fertility and result in miscarriages, stillbirths, and cancers in healthcare staff. Several recommended practices aim to reduce this exposure, including protective clothing, gloves, and biological safety cabinets ('safe handling'). There is significant uncertainty as to whether using closed‐system drug‐transfer devices (CSTD) in addition to safe handling decreases the contamination and risk of staff exposure to infusional hazardous drugs compared to safe handling alone. </p> </section> <section id="CD012860-sec-0002"> <h3 class="title" id="CD012860-sec-0002">Objectives</h3> <p>To assess the effects of closed‐system drug‐transfer of infusional hazardous drugs plus safe handling versus safe handling alone for reducing staff exposure to infusional hazardous drugs and risk of staff contamination, and to determine if the better reuse of multi‐dose vials leads to cost savings. </p> </section> <section id="CD012860-sec-0003"> <h3 class="title" id="CD012860-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, OSH‐UPDATE, CINAHL, Science Citation Index Expanded, economic evaluation databases, the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov to October 2017. </p> </section> <section id="CD012860-sec-0004"> <h3 class="title" id="CD012860-sec-0004">Selection criteria</h3> <p>We included comparative studies of any study design (irrespective of language, blinding, or publication status) that compared CSTD plus safe handling versus safe handling alone for infusional hazardous drugs. </p> </section> <section id="CD012860-sec-0005"> <h3 class="title" id="CD012860-sec-0005">Data collection and analysis</h3> <p>Two review authors independently identified trials and extracted data. We calculated the risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CI) using both fixed‐effect and random‐effects models. We assessed risk of bias according to the <b>r</b> isk <b>o</b> f <b>b</b> ias <b>i</b> n <b>n</b> on‐randomised <b>s</b> tudies of <b>i</b>nterventions (ROBINS‐I) tool, used an intracluster correlation coefficient of 0.10, and we assessed the quality of the evidence using GRADE. </p> </section> <section id="CD012860-sec-0006"> <h3 class="title" id="CD012860-sec-0006">Main results</h3> <p>We included 24 observational cluster studies (359 hospitals) in this review. We did not find any randomised controlled trials or formal economic evaluations. In 22 studies, the people who used the intervention (CSTD plus safe handling) and control (safe handling alone) were pharmacists or pharmacy technicians; in the other two studies, the people who used the intervention and control were nurses, pharmacists, or pharmacy technicians. Therefore, the evidence is mainly applicable to pharmacists or pharmacy technicians. The CSTD used in the studies were PhaSeal (13 studies), Tevadaptor (2 studies), SpikeSwan (1 study), PhaSeal and Tevadaptor (1 study), varied (5 studies), and not stated (2 studies). Therefore, the evidence is mainly applicable for PhaSeal. The studies' descriptions of the control groups were varied. Twenty‐two studies provide data on one or more outcomes for this systematic review. All the studies are at serious risk of bias. The quality of evidence is very low for all the outcomes. </p> <p>Very low certainty evidence from small studies is insufficient to determine whether there is any important difference between CSTD and control groups in the proportion of people with positive urine tests for exposure between the CSTD and control groups for any of the drugs: cyclophosphamide alone (RR 0.83, 95% CI 0.46 to 1.52; I² = 12%; 2 studies; 2 hospitals; 20 participants; CSTD: 76.1% versus control: 91.7%); cyclophosphamide or ifosfamide (RR 0.09, 95% CI 0.00 to 2.79; 1 study; 1 hospital; 14 participants; CSTD: 6.4% versus control: 71.4%); and cyclophosphamide, ifosfamide, or gemcitabine (RR not estimable; 1 study; 1 hospital; 36 participants; 0% in both groups). </p> <p>Very low certainty evidence from small studies is insufficient to determine whether there is any important difference between CSTD and control groups in the proportion of surfaces contaminated or the quantity of contamination. Overall, out of 24 comparisons in pharmacy areas or patient‐care areas, there was a reduction in the proportion of surfaces contaminated in only one comparison and out of 15 comparisons in pharmacy areas or patient‐care areas, there was a reduction in the quantity of contamination in only two comparisons. </p> <p>None of the studies report on atmospheric contamination, blood tests, or other measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, or micronuclei induction. </p> <p>None of the studies report short‐term health outcomes such as reduction in skin rashes, medium‐term reproductive health outcomes such as fertility and parity, or long‐term health outcomes related to the development of any type of cancer or adverse events. </p> <p>Five studies (six hospitals) report the potential cost savings through the use of CSTD. The studies used different methods of calculating the costs, and the results were not reported in a format that could be pooled via meta‐analysis. There is significant variability between the studies in terms of whether CSTD resulted in cost savings (the point estimates of the average potential cost savings ranged from (2017) USD −642,656 to (2017) USD 221,818). </p> <p>The healthcare professionals in the studies that provide data were mostly pharmacists or pharmacy technicians. Therefore, the evidence is mainly applicable to pharmacists and pharmacy technicians. Most of the studies that provide information for this review evaluated the use of PhaSeal; therefore the findings are mostly applicable to PhaSeal. </p> </section> <section id="CD012860-sec-0007"> <h3 class="title" id="CD012860-sec-0007">Authors' conclusions</h3> <p>Currently, no firm conclusions can be drawn on the effect of CSTD combined with safe handling versus safe handling alone due to very low certainty evidence available for the main outcomes. </p> <p>Multicentre randomised controlled trials may be feasible depending upon the proportion of people with exposure. The next best study design is interrupted time‐series. Future studies should evaluate exposure to a relevant selection of hazardous drugs used in the hospital, and they should measure direct short‐term health outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012860-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012860-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012860-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012860-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012860-abs-0005">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012860-abs-0003" lang="en"> <h3>Closed‐system drug‐transfer devices for reducing exposure to infusional hazardous medicines in healthcare staff </h3> <p>Some medicines – whether given as tablets or as a drip through the veins – are hazardous to the healthcare staff who handle them. Patients receive infusional hazardous medicines through the veins as treatment for serious diseases like cancer. When healthcare staff are exposed to these medicines, they can decrease their fertility and result in miscarriages, stillbirths, and cancers. Several recommended practices can reduce healthcare staff exposure to these hazardous medicines. These include protective clothing, gloves, and special cabinets where staff can prepare the hazardous medicines prior to giving them to patients. Together, these practices constitute 'safe handling'. A closed‐system drug‐transfer device (CSTD) is a device system that mechanically prevents the escape of hazardous drug outside the system. In addition, the systems also attempt to prevent microbiological contamination of the drug, potentially enabling reuse of multi‐dose vials (drug containers which have been designed in such a way that the medicines in the container can be used multiple times and for multiple patients) and decreasing the costs. </p> <p><b>What is the aim of this review?</b> </p> <p>There is significant uncertainty as to whether using CSTD in addition to safe handling decreases the exposure and risk of staff contamination to hazardous medicines compared to safe handling alone and whether CSTD can lead to cost‐savings by allowing better reuse of multi‐dose vials. We sought to resolve this issue by searching for existing studies on the topic. </p> <p><b>Key messages</b> </p> <p>Short or long‐term health outcomes were not reported in any studies. We found very low quality evidence (the best evidence available currently) that there is no considerable difference in exposure between CSTD plus safe handling versus safe handling alone. We also found very low quality evidence (the best evidence available currently) that there is no considerable effect of CSTD on the percentage of surfaces contaminated and the amount of contamination in in pharmacy and patient‐care areas for most drugs even though there was a small effect on contamination for one drug out of 24 studied and on amount of drug contamination for two drugs out of 15 studied . Therefore, no firm conclusions can be drawn on the effect of CSTD plus safe handling versus safe handling alone due to very low quality evidence available. Since most of the studies were conducted in pharmacy technicians and pharmacists and the CSTD used was PhaSeal, the evidence is applicable mainly to pharmacy technicians and pharmacists, and to PhaSeal. </p> <p><b>What was studied in the review?</b> </p> <p>We included all types of studies that compared CSTD plus safe handling ('CSTD group') and safe handling alone ('control group'). </p> <p><b>What are the main results of the review?</b> </p> <p>We included 24 studies (359 hospitals) in this review, none of which used the gold standard study design (randomised controlled trial) or explored a treatment's value for money. In 22 studies, the people who used the CSTD and safe handling were pharmacists or pharmacy technicians. Nineteen studies provide information that could be included for this study. </p> <p>No firm conclusion can be drawn on the effects of using CSTD on indirect measures of exposure such as the presence of the hazardous drug in the urine of the healthcare professionals or on the contamination of surfaces or the floor. </p> <p>There is significant variability between the studies in terms of whether the use of CSTD resulted in cost savings, with some studies reporting increased costs and others reporting decreased costs after introducing CSTD. None of the studies report on short or long‐term health outcomes such as reduction in skin rashes, infertility, miscarriage, development of any type of cancer, or adverse events. </p> <p>We judged the certainty of evidence for all outcomes to be very low because all the studies had one or more significant limitations in their design. Therefore, the reported effects of interventions are uncertain. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies up until 26 October 2017.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012860-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012860-sec-0087"></div> <h3 class="title" id="CD012860-sec-0088">Implications for practice</h3> <section id="CD012860-sec-0088"> <p>The available evidence does not support or refute the routine use of closed‐system drug transfer devices in addition to safe handling of infusional hazardous drugs, as the evidence is too uncertain to conclude that there are differences in exposure or financial benefits between CSTD plus safe handling versus safe handling alone. None of the studies report health benefits. </p> </section> <h3 class="title" id="CD012860-sec-0089">Implications for research</h3> <section id="CD012860-sec-0089"> <p>Future studies should be designed in such a way as to decrease the risk of bias.</p> <section id="CD012860-sec-0090"> <h5 class="title">Study design</h5> <p>Well‐designed multicentre randomised controlled trials may be feasible if the exposure, as measured by urine samples, is high (please see sample size calculations below). The next best study design is interrupted time‐series, which is likely to provide a better estimate than uncontrolled before‐after studies or cross‐sectional studies. In all types of study designs, investigators should take steps to ensure that there are no other differences between CSTD and control groups, so that they can obtain a reasonable estimate of decrease in exposure and the short‐term or long‐term health effects of using CSTD. This includes measures such as proper cleaning of the surfaces prior to exposure of both the intervention and control groups (i.e. all surfaces should be cleaned and samples taken to ensure that they are clean, followed by exposure to an equivalent period of time in the safe handling alone group as in the CSTD plus safe handling group), so that there is no residual contamination. Likewise, staff in both groups should receive an equal period of training for CSTD plus safe handling and safe handling alone of infusional hazardous drugs. This will ensure that the effect observed is the true effect due to CSTD. Other information of interest includes the annual drug use within the centre, description of the tasks performed by the staff, and the safe handling practices used, so that it is possible to estimate the effect of CSTD in different situations. Studies should register their protocol prospectively, for example in journal publications, ClinicalTrials.gov, or scientific repositories such as <a href="http://www.zenodo.org" target="_blank">zenodo.org</a>. </p> </section> <section id="CD012860-sec-0091"> <h5 class="title">Population</h5> <p>Staff exposed to infusional hazardous drugs.</p> </section> <section id="CD012860-sec-0092"> <h5 class="title">Study arms</h5> <p><b>Intervention</b>: CSTD plus safe handling. </p> <p><b>Control</b>: safe handling alone or other measures such as central priming of intravenous tubes, cleaning of vials, cleaning of surfaces, management of patient excreta and storage in addition to safe handling (multi‐arm randomised controlled trials or factorial trial design). </p> </section> <section id="CD012860-sec-0093"> <h5 class="title">Outcomes</h5> <p><b>Primary outcome</b>: exposure to an appropriate selection of hazardous drugs used in the hospitals. </p> <p><b>Secondary outcomes</b>: short‐term or long‐term health outcomes and cost‐effectiveness. </p> <p>In the future, studies using exposure as an outcome should measure exposure to a relevant selection of hazardous drugs in order to provide a reasonable estimate of the short‐term or long‐term health effects of using CSTD. Surface contamination should be considered less important than exposure. This is because the staff are exposed to other unmeasured hazardous drugs and contamination in patient‐care areas. Using surface contamination as the primary outcome has the potential to lead to complacency in handling drugs. </p> </section> <section id="CD012860-sec-0094"> <h5 class="title">Sample size calculations</h5> <p>The baseline risk of cancers in people exposed to hazardous drugs is 0.3% (<a href="./references#CD012860-bbs2-0135" title="RatnerPA , SpinelliJJ , BekingK , LorenziM , ChowY , TeschkeK , et al. Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs. BMC Nursing2010;9:15. ">Ratner 2010</a>). Using an alpha error of 5%, power of 80%, and a relative risk reduction of 20%, the unadjusted sample size required is 234,830. Using an ICC of 0.10 and the median cluster size of 13 observed in the studies that report on exposure, the sample size adjusted for clustering is 516,626. </p> <p>The baseline risk of congenital anomalies in women who were exposed to hazardous drugs is 0.1% to 6.0% (<a href="./references#CD012860-bbs2-0096" title="ConnorTH , LawsonCC , PolovichM , McDiarmidMA . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. Journal of Occupational and Environmental Medicine2014;56(9):901‐10. ">Connor 2014</a>). Using the median baseline risk of congenital anomalies and the same parameters as for the previous sample size calculation, the unadjusted sample size required is 30,078 and the adjusted sample size is 66,172. </p> <p>The risk of stillbirths, miscarriages, and tubal pregnancies in women exposed to hazardous drugs is 0.1% to 25.9%, depending on the methods used to calculate the risk (<a href="./references#CD012860-bbs2-0096" title="ConnorTH , LawsonCC , PolovichM , McDiarmidMA . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. Journal of Occupational and Environmental Medicine2014;56(9):901‐10. ">Connor 2014</a>). This results in an unadjusted sample size of 31,474 and an adjusted sample size of 69,243 using the median baseline risk of 2.2% and the same parameters of above. </p> <p>The true incidence of acute ill health effects due to exposure to infusional hazardous drugs is not known. Using an estimate of 5% of people using safe handling practices with the remaining parameters remaining the same as above, an unadjusted sample size of 13,492 and adjusted sample size of 29,682 is required. </p> <p>None of these outcomes can be explored in randomised controlled settings because these sample sizes are impractical, even if the ICC were much smaller than 0.10. About 77% of people using safe handling alone had hazardous drugs in their urine, based on the median baseline risk in the studies included in this systematic review. Using a relative risk reduction of 44% (median risk reduction in the three studies in which one or more people in the safe handling group had hazardous drugs in the urine), an alpha error of 5%, power of 80%, an ICC of 0.10, and a cluster size of 13, the unadjusted sample size required is 66 and the adjusted sample size is 145. This can be achieved, but requires multicentre studies. However, other studies have indicated that none of the healthcare staff had positive urine samples (<a href="./references#CD012860-bbs2-0130" title="PoupeauC , TanguayC , PlanteC , GagneS , CaronN , BussieresJF . Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers. Journal of Oncology Pharmacy Practice2017;23(5):323‐32. ">Poupeau 2017</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>), which may reflect high quality safety handling practices or differences in methodology used to collect urine (spot urine sample versus 24‐hour urine sample). If the rates of urinary exposure are low, then it will be difficult to conduct a randomised controlled trial, and interrupted time‐series may be a good alternative. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012860-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012860-sec-0015"></div> <div class="table" id="CD012860-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and surface contamination</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Closed‐system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and contamination</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : healthcare staff who handle infusional hazardous drugs<br/> <b>Settings</b> : hospitals<br/> <b>Intervention</b> : closed‐system transfer device plus safe handling<br/> <b>Control</b>: safe handling alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of hospitals<br/> (samples; studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Safe handling alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Closed‐system transfer device plus safe handling</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Exposure (urine tests for exposure)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide alone</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>761 per 1000</b><br/> (422 to 1393) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b><br/> (0.46 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 hospitals</p> <p>(20 participants; 2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide or ifosfamide</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/> (0 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b><br/> (0.00 to 2.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hospital</p> <p>(14 participants; 1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no participants with exposure in either group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 hospitals</p> <p>(36 participants; 1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of exposure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report on blood tests or other measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, or micronuclei induction. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surface contamination (proportion of surfaces contaminated)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Pharmacy areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/> (395 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/> (0.78 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338 hospitals<br/> (2937 samples; 13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/> (197 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/> (0.74 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 hospitals<br/> (2332 samples; 9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (59 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/> (0.58 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1781 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>149 per 1000</b><br/> (99 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.63<br/> (0.42 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 hospitals<br/> (1068 samples; 4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cytarabine</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b><br/> (48 to 762) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b><br/> (0.18 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 hospitals<br/> (780 samples; 2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gemcitabine</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b><br/> (193 to 496) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b><br/> (0.60 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 hospitals<br/> (780 samples; 2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, multiple drugs</i><sup>ϯ</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the proportion of samples contaminated with 5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, or multiple drugs in pharmacy areas between closed‐system transfer device plus safe handling versus safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irinotecan, docetaxel, paclitaxel, vinorelbine: 83 hospitals<br/> (493 samples; 1 study) </p> <p>Ganciclovir: 1 hospital<br/> (287 samples; 1 study) </p> <p>Epirubicin: 1 hospital (60 samples; 1 study)</p> <p>Multiple drugs: 4 hospitals<br/> (109 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Patient‐care areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/> (378 to 519) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.86 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/> (64 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b><br/> (0.91 to 2.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (14 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.55 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugs</i><sup>ϯ</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the proportion of samples contaminated with 5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugs in patient‐care areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine: 83 hospitals<br/> (493 samples; 1 study) </p> <p>Multiple drugs: 4 hospitals<br/> (33 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surface contamination (quantity of surface contamination (pg/cm²))</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Pharmacy areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i><sup>‡</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the control group is<br/> <b>124.30 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the intervention group is <b>49.34 pg/cm² lower</b><br/> (84.11 lower to 14.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −49.34 pg/cm²</b> </p> <p>(−84.11 to −14.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282 hospitals<br/> (1793 samples; 7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the control group is<br/> <b>10.8 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the intervention group is <b>0.32 pg/cm² lower</b><br/> (6.58 lower to 5.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −0.32 pg/cm²</b> </p> <p>(−6.58 to 5.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1749 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the control group is<br/> <b>18.23 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the intervention group is <b>3.09 pg/cm² lower</b><br/> (13.80 lower to 7.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −3.09 pg/cm²</b> </p> <p>(−13.80 to 7.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1749 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 5‐fluorouracil in the control group is<br/> 740 pg/cm² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 5‐fluorouracil in the intervention group is <b>231.62 pg/cm² higher</b> (460.52 lower to 923.76 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 231.62</b> </p> <p>(−460.52 to 923.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 hospitals<br/> (602 samples; 3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean epirubicin in the control group is<br/> 110 pg/cm² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean 5‐fluorouracil in the intervention group is <b>110.00 pg/cm² lower</b> (112.93 lower to 107.07 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD −110.00</b> (−112.93 to −107.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hospital<br/> (60 samples; 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cytarabine, gemcitabine, and irinotecan</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the amount of cytarabine, gemcitabine, and irinotecan in pharmacy areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 hospitals<br/> (493 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Patient‐care areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the control groups is<br/> <b>168 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the intervention group is<br/> <b>13.34 pg/cm² lower</b><br/> (36.01 lower to 9.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −13.34 pg/cm²</b> </p> <p>(−36.01 to 9.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the control group is<br/> <b>4.59 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the intervention group is<br/> <b>3.59 pg/cm² higher</b><br/> (3.45 lower to 10.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.59 pg/cm²</b> </p> <p>(−3.45 to 10.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the control groups is<br/> <b>1.42 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the intervention group is <b>0.10 pg/cm² higher</b><br/> (0.57 lower to 0.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.10 pg/cm²</b> </p> <p>(−0.57 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil, cytarabine, gemcitabine, and irinotecan</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the amount of 5‐fluorouracil, cytarabine, gemcitabine, and irinotecan in patient‐care areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 hospitals<br/> (460 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of contamination</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report on atmospheric contamination.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>MD</b> : mean difference; <b>RR</b>: risk ratio </p> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <sup>ϯ</sup>Report contains multiple drugs with no outcome information on individual drugs.<br/> <sup>‡</sup>In addition, one interrupted time‐series study (three hospitals; 342 samples) provided data on the quantity of contamination with cyclophosphamide from surface samples in pharmacy areas during three phases, initial phase of no CSTD, followed by CSTD, and then by no CSTD, each phase lasting three weeks (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>). The authors took biweekly measurements in all three phases. Between the first two phases, the change in the slope between pre‐CSTD and CSTD was 3.9439 pg/cm² (95% CI 1.2303 to 6.6576; P = 0.01). Between the second and third phases, the slope and level were expected to rise again but the change in the slope between CSTD and post‐CSTD withdrawal was −1.9331 pg/cm², 95% CI −5.126 to 1.2598 (P = 0.200) and the level was 14.167 pg/cm² (SD = 10.619). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The study or studies was or were at serious risk of bias (downgraded one level for risk of bias).<br/> <sup>b</sup>The confidence intervals were wide (downgraded one level for imprecision).<br/> <sup>c</sup>The sample size was small (downgraded one level for imprecision).<br/> <sup>d</sup>This is a surrogate measure of health benefit (downgraded one level for indirectness).<br/> <sup>e</sup>There was possible evidence of publication bias (Egger's test P value &lt; 0.05) (downgraded one level for publication bias).<br/> <sup>f</sup>There is no evidence that this small difference in levels of cyclophosphamide leads to decreased exposure or tangible health benefits (downgraded one level for imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012860-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Closed‐system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population</b> : healthcare staff who handle infusional hazardous drugs<br/> <b>Settings</b> : hospitals<br/> <b>Intervention</b> : closed‐system transfer device plus safe handling<br/> <b>Control</b>: safe handling alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of hospitals<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Safe handling alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Closed‐system transfer device plus safe handling</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report health outcomes such as skin rashes, reproductive health effects (infertility or miscarriage), or development of any type of cancer. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Potential cost savings</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The studies used different methods of calculating the costs and reported results in formats that could not be pooled via meta‐analysis. There is significant variability between the studies in terms of whether the use of CSTD results in cost savings (the point estimates of the average potential cost savings ranged between (2017) US D−642,656 and (2017) USD +221,818*. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 hospitals<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*Negative sign indicates cost savings and positive sign indicate increased costs due to the use of closed‐system transfer device. </p> <p><b>CI</b> : confidence interval; <b>CSTD</b>: closed‐system transfer device. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The studies are at serious risk of bias (downgraded one level for risk of bias).<br/> <sup>b</sup>There is very serious inconsistency in magnitude and direction of effect (downgraded two levels for inconsistency). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012860-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012860-sec-0016"></div> <section id="CD012860-sec-0017"> <h3 class="title" id="CD012860-sec-0017">Description of the condition</h3> <p>Hazardous drugs include those used for cancer chemotherapy, antiviral drugs, hormones, some bioengineered drugs, and other drugs (<a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). Although there is some variation in the definition of hazardous drugs, the National Institute for Occupational Safety and Health (NIOSH) describes hazardous drugs as those that have the potential to cause one or more of the following: carcinogenicity (inducing cancer), teratogenicity (causing birth defects), developmental toxicity (having an adverse impact on development), reproductive toxicity (interfering with normal reproduction), organ toxicity at low doses (damaging organs), or genotoxicity (causing mutations, i.e. alterations in the genetic structure) (<a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). New drugs that have a structure and toxicity profile that mimics existing drugs considered hazardous according to the above criteria are also considered hazardous (<a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). There is a subtle difference between cytotoxic drugs and hazardous drugs. Cytotoxic drugs are medicines that are toxic to human cells (<a href="./references#CD012860-bbs2-0125" title="National Center for Biotechnology Information. Cytotoxins, 1978. www.ncbi.nlm.nih.gov/mesh/68003603 (accessed 7 June 2017). ">NCBI 1978</a>), while hazardous drugs include cytotoxic drugs and new drugs that have a structure and toxicity profile similar to cytotoxic drugs. </p> <p>The various types of hazardous drugs include alkylating drugs (e.g. cyclophosphamide, chlorambucil), anthracyclines and other cytotoxic antibiotics (e.g. daunorubicin, doxorubicin), antimetabolites (e.g. methotrexate, fluorouracil, gemcitabine), vinca alkaloids and etoposide (e.g. vinblastine, vincristine), and some antineoplastic drugs (e.g. bevacizumab, denosumab, pertuzumab, rituximab, trastuzumab, mitotane) (<a href="./references#CD012860-bbs2-0088" title="British National Formulary. Cytotoxic drugs, 2017. bnf.nice.org.uk/treatment‐summary/cytotoxic‐drugs.html (accessed 7 June 2017). ">BNF 2017</a>). The mechanism of action varies between different types of cytotoxic drugs. In general, cytotoxic drugs interfere with cell replication by damaging DNA or by preventing normal cell division (<a href="./references#CD012860-bbs2-0088" title="British National Formulary. Cytotoxic drugs, 2017. bnf.nice.org.uk/treatment‐summary/cytotoxic‐drugs.html (accessed 7 June 2017). ">BNF 2017</a>). </p> <p>Cytotoxic drugs have anticancer activity and immunosuppressive properties (<a href="./references#CD012860-bbs2-0089" title="BroganPA , DillonMJ . The use of immunosuppressive and cytotoxic drugs in non‐malignant disease. Archives of Disease in Childhood2000;83(3):259‐64. ">Brogan 2000</a>). Therefore, they are used in the treatment of many cancers (e.g. breast cancer, bowel cancer, stomach cancer, sarcoma, leukaemia) and non‐cancerous conditions that require immunosuppression (e.g. polyarteritis nodosa, Wegener's granulomatosis, systemic lupus erythematosus, idiopathic nephrotic syndrome, inflammatory bowel disease, mixed connective tissue disease, scleroderma, multiple sclerosis, idiopathic inflammatory myopathy, sarcoidosis, primary membranous nephropathy, membranoproliferative glomerulonephritis, transplantation) (<a href="./references#CD012860-bbs2-0082" title="AwadA , StuveO . Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Therapeutic Advances in Neurological Disorders2009;2(6):50‐61. ">Awad 2009</a>; <a href="./references#CD012860-bbs2-0088" title="British National Formulary. Cytotoxic drugs, 2017. bnf.nice.org.uk/treatment‐summary/cytotoxic‐drugs.html (accessed 7 June 2017). ">BNF 2017</a>; <a href="./references#CD012860-bbs2-0089" title="BroganPA , DillonMJ . The use of immunosuppressive and cytotoxic drugs in non‐malignant disease. Archives of Disease in Childhood2000;83(3):259‐64. ">Brogan 2000</a>; <a href="./references#CD012860-bbs2-0092" title="CassidyJ , SaltzL , TwelvesC , VanCutsemE , HoffP , KangY , et al. Efficacy of capecitabine versus 5‐fluorouracil in colorectal and gastric cancers: a meta‐analysis of individual data from 6171 patients. Annals of Oncology2011;22(12):2604‐9. ">Cassidy 2011</a>; <a href="./references#CD012860-bbs2-0102" title="Fernandes Moca TrevisaniV , CastroAA , Ferreira Neves NetoJ , AtallahAN . Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database of Systematic Reviews2013, Issue 2. [DOI: 10.1002/14651858.CD002265.pub3] ">Fernandes Moca Trevisani 2013</a>; <a href="./references#CD012860-bbs2-0105" title="GeY , PengQ , ZhangS , ZhouH , LuX , WangG . Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clinical Rheumatology2015;34(1):99‐105. ">Ge 2015</a>; <a href="./references#CD012860-bbs2-0107" title="HartmanAR , FlemingGF , DillonJJ . Meta‐analysis of adjuvant cyclophosphamide/methotrexate/5‐fluorouracil chemotherapy in postmenopausal women with estrogen receptor‐positive, node‐positive breast cancer. Clinical Breast Cancer2001;2(2):138‐43. ">Hartman 2001</a>; <a href="./references#CD012860-bbs2-0108" title="HazlewoodGS , BarnabeC , TomlinsonG , MarshallD , DevoeDJ , BombardierC . Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis. Cochrane Database of Systematic Reviews2016, Issue 8. [DOI: 10.1002/14651858.CD010227.pub2] ">Hazlewood 2016</a>; <a href="./references#CD012860-bbs2-0123" title="MulderRL , PaulidesM , LangerT , KremerLC , vanDalenEC . Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD006300.pub2] ">Mulder 2015</a>; <a href="./references#CD012860-bbs2-0127" title="NunesAA , daSilvaAS , SouzaKM , Koury CdeN , deMelloLM . Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: a systematic review with meta‐analysis. Critical Reviews in Oncology/Hematology2015;94(3):261‐9. ">Nunes 2015</a>; <a href="./references#CD012860-bbs2-0129" title="PoormoghimH , Moradi LakehM , MohammadipourM , SodagariF , ToofaninjedN . Cyclophosphamide for scleroderma lung disease: a systematic review and meta‐analysis. Rheumatology International2012;32(8):2431‐44. ">Poormoghim 2012</a>; <a href="./references#CD012860-bbs2-0137" title="Rodriguez‐PeralvarezM , Guerrero‐MisasM , ThorburnD , DavidsonBR , TsochatzisE , GurusamyKS . Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis. Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD011639.pub2] ">Rodriguez‐Peralvarez 2017</a>; <a href="./references#CD012860-bbs2-0147" title="ZhuLB , LiuLL , YaoL , WangLN . Efficacy and safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: a meta‐analysis. Drugs2017;77(2):187‐99. ">Zhu 2017</a>). </p> <p>Hazardous drugs can be administered orally, intravenously by infusions, or intrathecally (<a href="./references#CD012860-bbs2-0088" title="British National Formulary. Cytotoxic drugs, 2017. bnf.nice.org.uk/treatment‐summary/cytotoxic‐drugs.html (accessed 7 June 2017). ">BNF 2017</a>). When hazardous drugs are given by intravenous infusion, there is a risk of contamination, which means that staff handling the infusional hazardous drugs, particularly the pharmacy technicians who prepare the drugs and the nurses who administer them, may come into contact with them. The hazardous drug aerosol, formed due to the spillage of drugs during preparation, transport, or administration, can be inhaled or absorbed through the skin (<a href="./references#CD012860-bbs2-0093" title="ChuWC , HonCY , DanylukQ , ChuaPP , AstrakianakisG . Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre‐ and post‐cleaning. Journal of Oncology Pharmacy Practice2012;18(1):46‐51. ">Chu 2012</a>; <a href="./references#CD012860-bbs2-0112" title="HonCY , TeschkeK , DemersPA , VennersS . Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Annals of Occupational Hygiene2014;58(6):761‐70. ">Hon 2014</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0133" title="RamphalR , BainsT , VaillancourtR , OsmondMH , BarrowmanN . Occupational exposure to cyclophosphamide in nurses at a single center. Journal of Occupational and Environmental Medicine/American College of Occupational and Environmental Medicine2014;56(3):304‐12. ">Ramphal 2014</a>; <a href="./references#CD012860-bbs2-0139" title="SchierlR , MasiniC , GroeneveldS , FischerE , BohlandtA , RosiniV , et al. Environmental contamination by cyclophosphamide preparation: comparison of conventional manual production in biological safety cabinet and robot‐assisted production by APOTECAchemo. Journal of Oncology Pharmacy Practice2016;22(1):37‐45. ">Schierl 2016</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0140" title="SessinkPJ , LeclercqGM , WoutersDM , HalbardierL , HammadC , KassoulN . Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. Journal of Oncology Pharmacy Practice2015;21(2):118‐27. ">Sessink 2015</a>; <a href="./references#CD012860-bbs2-0143" title="SugiuraS , AsanoM , KinoshitaK , TanimuraM , NabeshimaT . Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. Journal of Oncology Pharmacy Practice2011;17(1):14‐9. ">Sugiura 2011</a>; <a href="./references#CD012860-bbs2-0145" title="ViegasS , PaduaM , VeigaAC , CarolinoE , GomesM . Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environmental Monitoring and Assessment2014;186(11):7807‐18. ">Viegas 2014</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>; <a href="./references#CD012860-bbs2-0079" title="YoshidaJ , KodaS , NishidaS , NakanoH , TeiG , KumagaiS . Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Annals of Occupational Hygiene2013;57(2):251‐60. ">Yoshida 2013</a>). Other staff (e.g. pharmacists, respiratory therapists, physicians, support staff) working in the hospital that administers hazardous drugs can also be exposed to the contamination, not just those who handle the hazardous drugs) (<a href="./references#CD012860-bbs2-0112" title="HonCY , TeschkeK , DemersPA , VennersS . Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Annals of Occupational Hygiene2014;58(6):761‐70. ">Hon 2014</a>; <a href="./references#CD012860-bbs2-0133" title="RamphalR , BainsT , VaillancourtR , OsmondMH , BarrowmanN . Occupational exposure to cyclophosphamide in nurses at a single center. Journal of Occupational and Environmental Medicine/American College of Occupational and Environmental Medicine2014;56(3):304‐12. ">Ramphal 2014</a>). </p> <p>Occupational exposure to hazardous drugs increases mutations that predispose the exposed staff to the development of cancer (<a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0119" title="MahmoodiM , Soleyman‐JahiS , ZendehdelK , MozdaraniH , AzimiC , FarzanfarF , et al. Chromosomal aberrations, sister chromatid exchanges, and micronuclei in lymphocytes of oncology department personnel handling anti‐neoplastic drugs. Drug and Chemical Toxicology2017;40(2):235‐40. ">Mahmoodi 2017</a>; <a href="./references#CD012860-bbs2-0058" title="McDiarmidMA , OliverMS , RothTS , RogersB , EscalanteC . Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. Journal of Occupational and Environmental Medicine2010;52(10):1028‐34. ">McDiarmid 2010</a>; <a href="./references#CD012860-bbs2-0121" title="McDiarmidMA , RogersB , OliverMS . Chromosomal effects of non‐alkylating drug exposure in oncology personnel. Environmental and Molecular Mutagenesis2014;55(4):369‐74. ">McDiarmid 2014</a>; <a href="./references#CD012860-bbs2-0122" title="MorettiM , GrollinoMG , PavanelloS , BonfiglioliR , VillariniM , AppolloniM , et al. Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach. International Archives of Occupational and Environmental Health2015;88(6):683‐95. ">Moretti 2015</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>; <a href="./references#CD012860-bbs2-0141" title="SkovT , MaarupB , OlsenJ , RorthM , WinthereikH , LyngeE . Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. British Journal of Industrial Medicine1992;49(12):855‐61. ">Skov 1992</a>). Maternal occupational exposure to hazardous drugs during pregnancy can cause congenital abnormalities, miscarriages, stillbirths, and low birthweight (<a href="./references#CD012860-bbs2-0096" title="ConnorTH , LawsonCC , PolovichM , McDiarmidMA . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. Journal of Occupational and Environmental Medicine2014;56(9):901‐10. ">Connor 2014</a>; <a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). Occupational exposure to hazardous drugs can also decrease fertility in women (<a href="./references#CD012860-bbs2-0096" title="ConnorTH , LawsonCC , PolovichM , McDiarmidMA . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. Journal of Occupational and Environmental Medicine2014;56(9):901‐10. ">Connor 2014</a>; <a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). Other adverse effects include skin rash, hair loss, light‐headedness, abnormal blood counts, liver damage, abdominal pain, and vomiting (<a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). </p> <p>Several methods have been proposed to decrease the risk of exposure to hazardous drugs. These include the use of biological safety cabinets with laminar airflow for drug preparation, robotic drug preparation, centralisation of priming of intravenous tubing, personal protective equipment, staff education for safe handling of hazardous drugs, and closed‐system drug transfer devices (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0139" title="SchierlR , MasiniC , GroeneveldS , FischerE , BohlandtA , RosiniV , et al. Environmental contamination by cyclophosphamide preparation: comparison of conventional manual production in biological safety cabinet and robot‐assisted production by APOTECAchemo. Journal of Oncology Pharmacy Practice2016;22(1):37‐45. ">Schierl 2016</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0140" title="SessinkPJ , LeclercqGM , WoutersDM , HalbardierL , HammadC , KassoulN . Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation. Journal of Oncology Pharmacy Practice2015;21(2):118‐27. ">Sessink 2015</a>; <a href="./references#CD012860-bbs2-0079" title="YoshidaJ , KodaS , NishidaS , NakanoH , TeiG , KumagaiS . Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Annals of Occupational Hygiene2013;57(2):251‐60. ">Yoshida 2013</a>). There are several guidelines for safe handling of hazardous drugs including those issued by the UK Health and Safety Executive (HSE), NHS Pharmaceutical Quality Assurance Committee, US NIOSH, US Pharmacopeial Convention (USP), Program in Evidence‐Based Care guidelines, International Society of Oncology Pharmacy Practitioners Standards, American Society of Health‐System Pharmacists, and Association paritaire pour la santé et la sécurité du travail du secteur affaires sociales (ASSTSAS) (<a href="./references#CD012860-bbs2-0081" title="ASSTSAS . Prevention Guide Safe Handling of Hazardous Drugs, 2008. asstsas.qc.ca/sites/default/files/publications/documents/Guides_Broch_Depl/GP65A_hazardous_drugs.pdf (accessed 27 June 2017). ">ASSTSAS 2008</a>; <a href="./references#CD012860-bbs2-0080" title="American Society of Health‐System Pharmacists. ASHP guidelines on handling hazardous drugs. American Journal of Health‐System Pharmacy2006;63(12):1172‐91. ">ASHP 2006</a>; <a href="./references#CD012860-bbs2-0085" title="BatemanR , SantilloM , HardyL , Lennan E (NHS Pharmaceutical Quality Assurance Committee). Guidance on the safe handling of monoclonal antibody (mAb) products, 5th edition, 2015. ukons.org/downloads/Proposed_national_requirements_for_overlabelling_of_foreign_%28non‐English_language%29_imported_medicines.pdf (accessed 27 June 2017). ">Bateman 2015</a>; <a href="./references#CD012860-bbs2-0097" title="EastyAC , CoakleyN , ChengR , CividinoM , SavageP , TozerR , et al. Safe handling of cytotoxics: guideline recommendations. Current Oncology2015;22(1):e27‐37. ">Easty 2015</a>; <a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0116" title="International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. Journal of Oncology Pharmacy Practice2007;13(Suppl):1‐81. ">ISOPP 2007</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>; <a href="./references#CD012860-bbs2-0144" title="US Pharmacopeial Convention(USP) . General chapter &lt;800&gt; Hazardous drugs ‐ handling in healthcare settings, 2017. www.usp.org/compounding/general‐chapter‐hazardous‐drugs‐handling‐healthcare (accessed 14 October 2017). ">USP 2017</a>). Broadly, these guidelines recommend the identification of the risk, use of biological safety cabinets, use of closed‐system drug‐transfer devices where reasonably practicable, and control of exposure at source (e.g. by using adequate extraction systems and appropriate organisational measures, issuing personal protective equipment, monitoring exposure at the workplace, providing health surveillance programmes, providing employee information and training, maintaining equipment appropriately, having appropriate procedures for dealing with spillages or contamination of people or work surfaces, and providing safe waste disposal) (<a href="./references#CD012860-bbs2-0081" title="ASSTSAS . Prevention Guide Safe Handling of Hazardous Drugs, 2008. asstsas.qc.ca/sites/default/files/publications/documents/Guides_Broch_Depl/GP65A_hazardous_drugs.pdf (accessed 27 June 2017). ">ASSTSAS 2008</a>; <a href="./references#CD012860-bbs2-0080" title="American Society of Health‐System Pharmacists. ASHP guidelines on handling hazardous drugs. American Journal of Health‐System Pharmacy2006;63(12):1172‐91. ">ASHP 2006</a>; <a href="./references#CD012860-bbs2-0085" title="BatemanR , SantilloM , HardyL , Lennan E (NHS Pharmaceutical Quality Assurance Committee). Guidance on the safe handling of monoclonal antibody (mAb) products, 5th edition, 2015. ukons.org/downloads/Proposed_national_requirements_for_overlabelling_of_foreign_%28non‐English_language%29_imported_medicines.pdf (accessed 27 June 2017). ">Bateman 2015</a>; <a href="./references#CD012860-bbs2-0097" title="EastyAC , CoakleyN , ChengR , CividinoM , SavageP , TozerR , et al. Safe handling of cytotoxics: guideline recommendations. Current Oncology2015;22(1):e27‐37. ">Easty 2015</a>; <a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0116" title="International Society of Oncology Pharmacy Practitioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. Journal of Oncology Pharmacy Practice2007;13(Suppl):1‐81. ">ISOPP 2007</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>; <a href="./references#CD012860-bbs2-0144" title="US Pharmacopeial Convention(USP) . General chapter &lt;800&gt; Hazardous drugs ‐ handling in healthcare settings, 2017. www.usp.org/compounding/general‐chapter‐hazardous‐drugs‐handling‐healthcare (accessed 14 October 2017). ">USP 2017</a>). </p> </section> <section id="CD012860-sec-0018"> <h3 class="title" id="CD012860-sec-0018">Description of the intervention</h3> <p>A closed‐system drug‐transfer device is an apparatus that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapour outside the system (<a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). Some examples of closed‐system drug‐transfer devices are: PhaSeal system, ChemoClave system, Equashield system, and Chemo Safety system. These devices include a method to access the intravenous infusion (e.g. a spike designed to prevent leaks and spillages), and a leak‐proof connection that attempts to transfer drugs without leaks or spillage, as a minimum (<a href="./references#CD012860-bbs2-0083" title="BBraun . Onguard® closed system transfer device (CSTD), 2017. www.bbraunusa.com/products.html?prid=PRID00006969 (accessed 7 June 2017). ">B Braun 2017a</a>; <a href="./references#CD012860-bbs2-0086" title="BectonDickinson . BD PhaSeal system for hazardous drug handling. System components, 2017. www.bd.com/pharmacy/phaseal/components.asp (accessed 7 June 2017). ">BD 2017a</a>; <a href="./references#CD012860-bbs2-0087" title="BectonDickinson . Chemo Safety system, 2017. www.carefusion.com/our‐products/infusion/iv‐therapy/chemo‐safety‐system (accessed 7 June 2017). ">BD 2017b</a>; <a href="./references#CD012860-bbs2-0099" title="EquashieldLLC . Equashield, 2017. www.equashield.com/ (accessed 7 June 2017). ">Equashield 2017</a>; <a href="./references#CD012860-bbs2-0114" title="ICU Medical Inc. ChemoClave needlefree closed systems and closed system transfer devices (CSTDs), 2017. www.icumed.com/products/oncology/hazardous‐drug‐closed‐systems‐and‐cstds/chemoclave.aspx (accessed 7 June 2016). ">ICUMED 2017</a>). However, some devices used in compounding hazardous drugs are not fully considered closed‐system drug‐transfer devices, as they are not conceived or have not been demonstrated to capture aerosols such as hydrophobic‐air‐venting filters or chemotherapy transfer/reconstitution spikes (<a href="./references#CD012860-bbs2-0084" title="BBraun . 0.2 micron air venting filter, hydrophobic, 2017. us.bbraunoem.com/cps/rde/xchg/oem‐bbraunoem‐en‐us/hs.xsl/products.html?prid=S4001002 (accessed 23 June 2017). ">B Braun 2017b</a>; <a href="./references#CD012860-bbs2-0109" title="Healthmark. Chemo spikes: chemotherapy reconstitution spikes, 2017. www.healthmark.ca/2‐36‐10‐Chemo‐Spikes_en.html?ProduitID=21 (accessed 23 June 2017). ">Healthmark 2017</a>). In this review, we will accept any device described as a closed‐system drug‐transfer device by the manufacturer. </p> </section> <section id="CD012860-sec-0019"> <h3 class="title" id="CD012860-sec-0019">How the intervention might work</h3> <p>Closed‐system drug‐transfer devices work by attempting to provide a leak‐proof connection that prevents leaks and spills (<a href="./references#CD012860-bbs2-0083" title="BBraun . Onguard® closed system transfer device (CSTD), 2017. www.bbraunusa.com/products.html?prid=PRID00006969 (accessed 7 June 2017). ">B Braun 2017a</a>; <a href="./references#CD012860-bbs2-0086" title="BectonDickinson . BD PhaSeal system for hazardous drug handling. System components, 2017. www.bd.com/pharmacy/phaseal/components.asp (accessed 7 June 2017). ">BD 2017a</a>; <a href="./references#CD012860-bbs2-0087" title="BectonDickinson . Chemo Safety system, 2017. www.carefusion.com/our‐products/infusion/iv‐therapy/chemo‐safety‐system (accessed 7 June 2017). ">BD 2017b</a>; <a href="./references#CD012860-bbs2-0099" title="EquashieldLLC . Equashield, 2017. www.equashield.com/ (accessed 7 June 2017). ">Equashield 2017</a>; <a href="./references#CD012860-bbs2-0114" title="ICU Medical Inc. ChemoClave needlefree closed systems and closed system transfer devices (CSTDs), 2017. www.icumed.com/products/oncology/hazardous‐drug‐closed‐systems‐and‐cstds/chemoclave.aspx (accessed 7 June 2016). ">ICUMED 2017</a>). This may decrease surface contamination and atmospheric contamination (with drug aerosol), thereby decreasing occupational exposure to infusional hazardous drugs. This in turn might result in fewer adverse events related to exposure. In addition, the systems also attempt to prevent microbiological contamination of the drug (<a href="./references#CD012860-bbs2-0086" title="BectonDickinson . BD PhaSeal system for hazardous drug handling. System components, 2017. www.bd.com/pharmacy/phaseal/components.asp (accessed 7 June 2017). ">BD 2017a</a>; <a href="./references#CD012860-bbs2-0099" title="EquashieldLLC . Equashield, 2017. www.equashield.com/ (accessed 7 June 2017). ">Equashield 2017</a>; <a href="./references#CD012860-bbs2-0114" title="ICU Medical Inc. ChemoClave needlefree closed systems and closed system transfer devices (CSTDs), 2017. www.icumed.com/products/oncology/hazardous‐drug‐closed‐systems‐and‐cstds/chemoclave.aspx (accessed 7 June 2016). ">ICUMED 2017</a>), potentially enabling reuse of vials and decreasing the costs. </p> </section> <section id="CD012860-sec-0020"> <h3 class="title" id="CD012860-sec-0020">Why it is important to do this review</h3> <p>There is significant variation in the way hazardous drugs are handled by staff. Legislation requires organisations to protect workers' health and safety (<a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>). All the staff working in hospitals that administer hazardous drugs are at potential risk of exposure to the drugs, which can result in the serious consequences described above (see <a href="#CD012860-sec-0017">Description of the condition</a>). Even when staff handle hazardous drugs according to all instructions and as safely as possible, there is still the possibility of accidental contamination of surfaces around them, which exposes other staff members to the drugs and their serious consequences. Therefore, it is important to use the most effective methods to decrease the risk of staff contact with infusional hazardous drugs. Some studies have shown that closed‐system drug‐transfer devices may decrease surface contamination compared to current safe handling practices including biological safety cabinets and use of personal protective equipment (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>). However, there are additional costs associated with using closed‐system drug‐transfer devices compared to safe handling of infusional hazardous drugs, and it is unclear whether these devices provide good value for money (i.e. whether the cost‐benefit ratio is favourable to using closed‐system drug‐transfer devices compared to conventional safe handling of infusional hazardous drugs). There is also major uncertainty about whether these devices are effective in reducing the risk of exposure. In one study, pharmacists considered that the use of a closed‐system drug‐transfer device increased technical issues, increased the risk of spillage, was slower and more cumbersome to use, and increased the risk of drug absorption through the skin and by inhalation (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>). In addition, there is concern that the observed differences in surface contamination attributed to the addition of closed‐system drug‐transfer devices to safe handling could actually be due to differences in the removal of previous drug residue. Further concerns include the possible contamination of the exterior of the hazardous drug vials at the manufacturing site (<a href="./references#CD012860-bbs2-0094" title="ConnorTH , SessinkPJ , HarrisonBR , PrettyJR , PetersBG , AlfaroRM , et al. Surface contamination of chemotherapy drug vials and evaluation of new vial‐cleaning techniques: results of three studies. American Journal of Health‐System Pharmacy2005;62(5):475‐84. ">Connor 2005</a>; <a href="./references#CD012860-bbs2-0101" title="FavierB , GillesL , ArdietC , LatourJF . External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. Journal of Oncology Pharmacy Practice2003;9(1):15‐20. ">Favier 2003</a>; <a href="./references#CD012860-bbs2-0104" title="Fleury‐SouverainS , NussbaumerS , MattiuzzoM , BonnabryP . Determination of the external contamination and cross‐contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. Journal of Oncology Pharmacy Practice2014;20(2):100‐1. ">Fleury‐Souverain 2014</a>; <a href="./references#CD012860-bbs2-0110" title="HedmerM , GeorgiadiA , BrembergER , JonssonBA , EksborgS . Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Annals of Occupational Hygiene2005;49(7):629‐37. ">Hedmer 2005</a>; <a href="./references#CD012860-bbs2-0120" title="MasonHJ , MortonJ , GarfittSJ , IqbalS , JonesK . Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Annals of Occupational Hygiene2003;47(8):681‐5. ">Mason 2003</a>; <a href="./references#CD012860-bbs2-0124" title="NaitoT , OsawaT , SuzukiN , GotoT , TakadaA , NakamichiH , et al. Comparison of contamination levels on the exterior surfaces of vials containing platinum anticancer drugs in Japan. Biological &amp; Pharmaceutical Bulletin2012;35(11):2043‐9. ">Naito 2012</a>), which may decrease the effectiveness of the closed‐system drug‐transfer devices in real‐life situations compared to controlled laboratory situations. Several studies have shown high levels of drug vial exterior contamination (<a href="./references#CD012860-bbs2-0094" title="ConnorTH , SessinkPJ , HarrisonBR , PrettyJR , PetersBG , AlfaroRM , et al. Surface contamination of chemotherapy drug vials and evaluation of new vial‐cleaning techniques: results of three studies. American Journal of Health‐System Pharmacy2005;62(5):475‐84. ">Connor 2005</a>; <a href="./references#CD012860-bbs2-0101" title="FavierB , GillesL , ArdietC , LatourJF . External contamination of vials containing cytotoxic agents supplied by pharmaceutical manufacturers. Journal of Oncology Pharmacy Practice2003;9(1):15‐20. ">Favier 2003</a>; <a href="./references#CD012860-bbs2-0104" title="Fleury‐SouverainS , NussbaumerS , MattiuzzoM , BonnabryP . Determination of the external contamination and cross‐contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. Journal of Oncology Pharmacy Practice2014;20(2):100‐1. ">Fleury‐Souverain 2014</a>; <a href="./references#CD012860-bbs2-0110" title="HedmerM , GeorgiadiA , BrembergER , JonssonBA , EksborgS . Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Annals of Occupational Hygiene2005;49(7):629‐37. ">Hedmer 2005</a>; <a href="./references#CD012860-bbs2-0120" title="MasonHJ , MortonJ , GarfittSJ , IqbalS , JonesK . Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Annals of Occupational Hygiene2003;47(8):681‐5. ">Mason 2003</a>; <a href="./references#CD012860-bbs2-0124" title="NaitoT , OsawaT , SuzukiN , GotoT , TakadaA , NakamichiH , et al. Comparison of contamination levels on the exterior surfaces of vials containing platinum anticancer drugs in Japan. Biological &amp; Pharmaceutical Bulletin2012;35(11):2043‐9. ">Naito 2012</a>), although there are exceptions to this (<a href="./references#CD012860-bbs2-0131" title="PowerLA , SessinkPJ , GesyK , CharbonneauF . Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Hospital Pharmacy2014;49(4):355‐62. ">Power 2014</a>). The risk of contamination may be dependent upon the manufacturing process used, for example due to different decontamination procedures and the encasing of the vials using protective sleeves (<a href="./references#CD012860-bbs2-0094" title="ConnorTH , SessinkPJ , HarrisonBR , PrettyJR , PetersBG , AlfaroRM , et al. Surface contamination of chemotherapy drug vials and evaluation of new vial‐cleaning techniques: results of three studies. American Journal of Health‐System Pharmacy2005;62(5):475‐84. ">Connor 2005</a>; <a href="./references#CD012860-bbs2-0131" title="PowerLA , SessinkPJ , GesyK , CharbonneauF . Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Hospital Pharmacy2014;49(4):355‐62. ">Power 2014</a>). Because of the uncertainty in the effectiveness of the closed‐system drug‐transfer devices, there is variation in the recommendations of different guidelines about the use of these devices. For example, USP recommends mandatory use of closed‐system drug‐transfer devices for administration when the dosage form allows, while NIOSH only recommends considering their use when transferring hazardous drugs (<a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>; <a href="./references#CD012860-bbs2-0144" title="US Pharmacopeial Convention(USP) . General chapter &lt;800&gt; Hazardous drugs ‐ handling in healthcare settings, 2017. www.usp.org/compounding/general‐chapter‐hazardous‐drugs‐handling‐healthcare (accessed 14 October 2017). ">USP 2017</a>). Furthermore, the staff handling hazardous drugs may be anxious about the serious consequences and want to know how well these devices protect them. </p> <p>Other purposes of the device, a more efficient use of drugs, could possibly lead to savings in the use of drugs because unused leftovers can be used for other patients. However, this is unrelated to worker protection but this could then be regarded as a free extra. Therefore, we wanted to know if the use of the devices led to more efficient use of drugs that could outweigh the device costs. </p> <p>There is currently no systematic review on the effect of closed‐system drug‐transfer devices versus conventional safe handling for reducing the risk of staff contamination to infusional hazardous drugs or their potential cost savings. This Cochrane Review will provide the best available evidence regarding this issue. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012860-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012860-sec-0021"></div> <p>To assess the effects of closed‐system drug‐transfer of infusional hazardous drugs plus safe handling versus safe handling alone for reducing staff exposure to infusional hazardous drugs and risk of staff contamination, and to determine if better reuse of multi‐dose vials leads to cost savings. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012860-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012860-sec-0022"></div> <section id="CD012860-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012860-sec-0024"> <h4 class="title">Types of studies</h4> <p>Due to the complex nature of the intervention, which is applied at the group level in work situations rather than at the individual level, randomised controlled trials (RCTs) are not very feasible, which is one of the major reasons for including non‐randomised studies in Cochrane Reviews (<a href="./references#CD012860-bbs2-0115" title="IjazS , VerbeekJH , MischkeC , RuotsalainenJ . Inclusion of nonrandomized studies in Cochrane systematic reviews was found to be in need of improvement. Journal of Clinical Epidemiology2014;67(6):645‐53. ">Ijaz 2014</a>). Therefore, we included other study designs in addition to RCTs. We considered comparative studies that are commonly performed in this field, that is, uncontrolled before‐after studies and cohort studies. We also included interrupted time‐series, controlled before‐after (CBA) studies, and case‐control studies. This is because interrupted time‐series may account for time trends in improvement of practices, and CBA studies may account for any interim changes in policies. We included case‐control studies because the outcomes following exposure are rare. </p> </section> <section id="CD012860-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included studies conducted on adult healthcare staff (aged 18 years or above) involved in the preparation, transport, delivery, administration, and disposal of waste of infusional hazardous drugs. We also considered healthcare organisations where healthcare staff were exposed to infusional hazardous drugs as participants with regards to outcomes such as surface contamination and aerosol contamination. </p> </section> <section id="CD012860-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included trials that evaluated the effectiveness of closed‐system drug transfer of infusional hazardous drugs (e.g. PhaSeal system and ChemoClave system) plus safe handling of infusional hazardous drugs (e.g. including class II biological safety cabinet, isolator, and personal protective equipment) versus safe handling alone. We accepted any device whose manufacturer described it as a closed‐system drug‐transfer device. We included trials with any co‐interventions provided they were not part of the randomised treatment or were applied equally in both arms in non‐randomised studies. </p> </section> <section id="CD012860-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD012860-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012860-list-0001"> <li> <p>Measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, and micronuclei induction </p> </li> <li> <p>Environmental contamination measured with surrogate outcomes for exposure: surface samples, splashes, leakage tests, or atmospheric contamination </p> </li> <li> <p>Short‐term health outcomes such as skin rashes</p> </li> <li> <p>Medium‐term health outcomes such as infertility or miscarriage</p> </li> <li> <p>Long‐term health outcomes such as cancer (any type of cancer)</p> </li> </ul> </p> <p>We accepted any methods used by the study authors, for example, routine screening for the presence or absence of outcomes or assessment of these outcomes in only people with symptoms suggestive of the presence of these outcomes. The Board of the UK Oncology Nursing Society identified these outcomes as the most important outcomes for the target population by as part of their funding call. </p> </section> <section id="CD012860-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012860-list-0002"> <li> <p>Adverse events (e.g. personal injury due to the use of spikes or needles resulting in infections) </p> </li> <li> <p>Potential cost savings due to reuse of multi‐dose vials</p> </li> </ul> </p> <p>We considered follow‐up times for primary and secondary outcome measurement as: short term (up to one year), medium term (one to five years), and long term (longer than five years). </p> <p>Reporting one or more of the primary or secondary outcomes listed here is not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD012860-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012860-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We conducted a systematic literature search to identify all published and unpublished trials that were potentially eligible for inclusion in this review. We adapted the search strategy developed for MEDLINE (see <a href="./appendices#CD012860-sec-0098">Appendix 1</a>) for use in the other electronic databases. We imposed no restrictions on language of publication and translated the key sections of potentially eligible non‐English language papers to assess them fully for potential inclusion in the review as necessary. </p> <p>We searched the following electronic databases from inception to 26 October 2017 to identify potential studies. The only exception was the databases searched through OSH‐UPDATE search platform, which we searched on 3 October 2017. </p> <p> <ul id="CD012860-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley Online Library) (<a href="./appendices#CD012860-sec-0099">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (OvidSP) (<a href="./appendices#CD012860-sec-0098">Appendix 1</a>). </p> </li> <li> <p>Embase (OvidSP) (<a href="./appendices#CD012860-sec-0100">Appendix 3</a>). </p> </li> <li> <p>NIOSHTIC (OSH‐UPDATE) (<a href="./appendices#CD012860-sec-0101">Appendix 4</a>). </p> </li> <li> <p>NIOSHTIC‐2 (OSH‐UPDATE) (<a href="./appendices#CD012860-sec-0101">Appendix 4</a>). </p> </li> <li> <p>HSELINE (OSH‐UPDATE) (<a href="./appendices#CD012860-sec-0101">Appendix 4</a>). </p> </li> <li> <p>CISDOC (OSH‐UPDATE) (<a href="./appendices#CD012860-sec-0101">Appendix 4</a>). </p> </li> <li> <p>CINAHL (EBSCO) (<a href="./appendices#CD012860-sec-0102">Appendix 5</a>). </p> </li> <li> <p>Science Citation Index Expanded (including Conference Proceedings) (<a href="./appendices#CD012860-sec-0103">Appendix 6</a>). </p> </li> <li> <p>NHS Economic Evaluation Database (NHS EED) (<a href="./appendices#CD012860-sec-0104">Appendix 7</a>). </p> </li> <li> <p>Cost‐Effectiveness Analysis Registry (CEA) at Tufts University (<a href="./appendices#CD012860-sec-0104">Appendix 7</a>). </p> </li> </ul> </p> <p>We also conducted a search for unpublished trials in ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) (<a href="./appendices#CD012860-sec-0105">Appendix 8</a>) on 26 October 2017. </p> </section> <section id="CD012860-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references and contacted experts in the field to identify additional unpublished material. </p> </section> </section> <section id="CD012860-sec-0033"> <h3 class="title" id="CD012860-sec-0033">Data collection and analysis</h3> <section id="CD012860-sec-0034"> <h4 class="title">Selection of studies</h4> <p>We conducted the selection of eligible studies in two stages. First, two review authors (KG and LB) independently screened titles and abstracts of all potentially relevant studies found with our systematic search to exclude studies that clearly did not fulfil the criteria for inclusion. CT identified additional studies by reviewing bibliographies to identify further full‐text records for potential inclusion. The same review authors coded records as 'include' (eligible or potentially eligible/unclear) or 'exclude'. We excluded all references that clearly did not fulfil our inclusion criteria or that fulfilled our exclusion criteria. Second, we retrieved the full‐text study reports/publications, and two review authors (KG and LB) independently assessed the full‐text to identify studies for inclusion. At this stage, we included all references that fulfilled our inclusion criteria. We recorded reasons for excluding studies based on assessment of the full text and reported these in a 'Characteristics of excluded studies' table. We resolved any disagreements through discussion. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA study flow diagram. </p> </section> <section id="CD012860-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We used an Excel‐based data collection form for study characteristics and outcome data that was piloted on two studies in the review. Two review authors (KG and LB) extracted the following study characteristics from included studies. </p> <p> <ul id="CD012860-list-0004"> <li> <p>Methods: study design, duration of study, study location, study setting, withdrawals, and date of study. </p> </li> <li> <p>Participants: number of participants, number of clusters (hospitals or wards), mean age or age range, sex, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: description of intervention, comparison (elements included in safe handling in the control group), and co‐interventions. </p> </li> <li> <p>Outcomes: description of primary and secondary outcomes specified and collected, and at which time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (KG and LB) independently extracted outcome data from included studies. We noted in the 'Characteristics of included studies' table if authors did not report outcome data in a usable way. We resolved disagreements by consensus. One review author (KG) transferred data into Review Manager 5 (<a href="./references#CD012860-bbs2-0136" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We double‐checked the data entry by comparing the data presented in the systematic review with the study reports. A third review author (CT) spot‐checked study characteristics and data for accuracy against the trial report. The author team was proficient in all languages of the studies included in the review (English and French). </p> </section> <section id="CD012860-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For each RCT, two review authors (KG and LB) independently planned to assess risk of bias using criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012860-bbs2-0111" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We planned to resolve any disagreements by discussion. We planned to assess the risk of bias according to the following domains. </p> <p> <ul id="CD012860-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias (including source of funding and whether the duration of exposure to hazardous drugs in the intervention group and control group was measured reliably after ensuring that the participants were free from the outcome at the beginning of the study). </p> </li> </ul> </p> <p>We planned to grade each potential risk of bias as high, low, or unclear, and we provided a quotation from the study report together with a justification for our judgement in the 'Risk of bias' table. We planned to summarise the risk of bias judgements across different studies for each of the domains listed. We planned to consider blinding separately for different key outcomes where necessary. To classify studies as being at low risk of bias in measurement of outcome, we required them to have carried out blinded assessment of all outcomes except for contamination of surface samples, where we accepted samples obtained and analysed by an automated machine as being at low risk of bias regardless of blinding. For urinary levels, we accepted this outcome as being at low risk of bias regardless of blinding. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we planned to note this in the 'Risk of bias' table. </p> <p>For each non‐randomised study, the same two review authors (KG and LB) assessed the risk of bias independently using the <b>r</b> isk <b>o</b> f <b>b</b> ias <b>i</b> n <b>n</b> on‐randomised <b>s</b> tudies of <b>i</b>nterventions (ROBINS‐I) tool (<a href="./references#CD012860-bbs2-0142" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016;355:i4919. ">Sterne 2016</a>). We considered the following as possible sources of confounding. </p> <p> <ul id="CD012860-list-0006"> <li> <p>Changes or differences in other factors for genetic and chromosomal damage such as stress from work, working long hours, and smoking that might lead to fewer genetic and chromosomal abnormalities compared to the intervention. </p> </li> <li> <p>Differences in drug residue on a surface prior to contamination (e.g. thorough cleaning before the study in only one group). </p> </li> <li> <p>Changes or differences in drug residue on the drug vials because of different batches or different manufacturers of the drug. </p> </li> </ul> </p> <p>In terms of bias due to classification of interventions, we considered studies to be at low risk of bias when it was clear that the intervention group was CSTD and the control group was no CSTD. </p> <p>We considered the following co‐interventions.</p> <p> <ul id="CD012860-list-0007"> <li> <p>Changes or differences in layout, ventilation, fume cupboards, etc., that might lead to less contamination compared to the intervention. </p> </li> <li> <p>Changes or differences in policies that might lead to less contamination compared to the intervention. </p> </li> <li> <p>Education, training, and experience of healthcare staff that might lead to less contamination compared to the intervention. </p> </li> <li> <p>Differences in the supervision for drug preparation or drug administration that might lead to less contamination compared to the intervention. </p> </li> </ul> </p> <p>We planned to assess the risk of bias in the included economic evaluations using either the Consensus Health Economic Criteria (CHEC) list for assessment of methodological quality of economic evaluations, described in <a href="./references#CD012860-bbs2-0100" title="EversS , GoossensM , deVetH , vanTulderM , AmentA . Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. International Journal of Technology Assessment in Health Care2005;21(2):240‐5. ">Evers 2005</a>, or the <a href="./references#CD012860-bbs2-0128" title="PhilipsZ , GinnellyL , SculpherM , ClaxtonK , GolderS , RiemsmaR , et al. Review of guidelines for good practice in decision‐analytic modelling in health technology assessment. Health Technology Assessment2004;8(36):1‐158. ">Philips 2004</a> checklist. </p> <p>We considered all domains other than blinding of healthcare providers to be key domains. We judged a study to be at high risk of bias overall when we judged one or more key domains to be at high risk of bias. Conversely, we judged a study to be at low risk of bias when we assigned a low risk of bias for all key domains. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD012860-sec-0037"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in <a href="#CD012860-sec-0119">Differences between protocol and review</a>. </p> </section> </section> <section id="CD012860-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We entered the outcome data for each study into the data tables in RevMan 5 to calculate the treatment effects unadjusted for clustering (<a href="./references#CD012860-bbs2-0136" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). As we did not find any case‐control studies, we used the risk ratio (RR) for dichotomous outcomes (this is because RRs are much easier to interpret; however, they cannot be calculated in case‐control studies without the use of risk from another study), and mean differences (MDs) for continuous outcomes. If studies reported only effect estimates and their 95% confidence intervals (CIs) or standard errors, we planned to enter these data into RevMan 5 using the generic inverse variance method (<a href="./references#CD012860-bbs2-0136" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We ensured that higher scores for continuous outcomes have the same meaning for the particular outcome. When the results could not be entered in either way, we entered the data into additional tables. </p> <p>For interrupted time‐series studies, we extracted data from the original papers and reanalysed them according to the recommended methods for analysing interrupted time‐series designs for inclusion in systematic reviews (<a href="./references#CD012860-bbs2-0134" title="RamsayCR , MatoweL , GrilliR , GrimshawJM , ThomasRE . Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care2003;19(4):613‐23. ">Ramsay 2003</a>). We planned to use the standardised change in level and change in slope as effect measures. </p> </section> <section id="CD012860-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>For studies that employed a cluster‐design and reported sufficient data to be included in the meta‐analysis but did not make an allowance for the design effect, we calculated the design effect based on a fairly large assumed intracluster correlation coefficient (ICC) of 0.10. We based this assumption of 0.10 being a realistic estimate by analogy with studies about implementation research (<a href="./references#CD012860-bbs2-0091" title="CampbellMK , MollisonJ , GrimshawJM . Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Statistics in Medicine2001;20(3):391‐9. ">Campbell 2001</a>). We followed the methods stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for the calculations, and we entered the data adjusted for clustering as generic inverse variance data (<a href="./references#CD012860-bbs2-0111" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This involved calculating the average cluster size 'M' (by dividing the total number of samples by the total number of hospitals) and calculating the design effect by using the formula 1 + (M − 1) ICC. We multiplied the standard error for each cluster study by the square root of the design effect to obtain a standard error adjusted for clustering. This adjusted standard error was then used to calculate the confidence intervals. </p> </section> <section id="CD012860-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was reported as abstract only). Where this was not possible, and if the missing data were thought to introduce serious bias, we would have explored the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> <p>If numerical outcome data were missing, such as standard deviations or correlation coefficients, and they could not be obtained from the authors, we planned to calculate them from other available statistics such as P values, according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012860-bbs2-0111" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD012860-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the clinical homogeneity of the results of included studies based on similarity of population, intervention, outcome, and follow‐up. We considered populations as similar when they were staff who were exposed to infusional hazardous drugs, for example, oncology nurses, pharmacy technicians, or pharmacists who handled infusional hazardous drugs. We considered interventions as similar when it was clear that the system was a closed‐system drug transfer device. We combined results data produced by each of the measures of contamination separately (e.g. urine tests, surface contamination, and atmospheric contamination), and we planned to combine cancer‐ and fertility‐related outcome data separately. We considered short‐term (up to one year), medium‐term (one to five years), and long‐term (more than five years) follow‐up times as different. </p> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (above 50%, as described in <a href="./references#CD012860-bbs2-0111" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), we planned to report it and explore possible causes by prespecified subgroup analysis. </p> </section> <section id="CD012860-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than five trials in any single meta‐analysis, we created and examined a funnel plot to explore possible small‐study biases. We used Egger's test to identify reporting biases (<a href="./references#CD012860-bbs2-0098" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). We considered a P value of less than 0.05 as statistically significant reporting bias. </p> </section> <section id="CD012860-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We pooled data from studies we judged to be clinically homogeneous using RevMan 5 software (<a href="./references#CD012860-bbs2-0136" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). If two or more studies provided usable data in any single comparison, we performed meta‐analyses. However, we did not plan to pool data from different study designs (i.e. RCT and non‐randomised studies). We analysed different drugs in separate analyses since drugs are reconstituted differently, administered differently (for example, some are intravenous only while others can be used intravenously, subcutaneously, or orally), used in different quantities, and can lead to different levels of exposure and contamination. Furthermore, these are dangerous at different dosages. In addition, we analysed the pharmacy areas and patient‐care areas separately since the levels of exposure and contamination vary between them. </p> <p>For costs, we used an international exchange rate based on purchasing power parities (PPP) to convert cost estimates to US dollars (USD), and we used the gross domestic product (GDP) deflators (or implicit price deflators for GDP) to convert cost estimates to 2017 USD using PPP conversion rates and GDP deflator values available from the International Monetary Fund in the World Economic Outlook Database (updated biannually: see <a href="http://www.imf.org/external/data.htm" target="_blank">www.imf.org/external/data.htm</a>). We used both a fixed‐effect model and a random‐effects model to perform the meta‐analyses and reported the more conservative model. When the I² statistic was higher than 75%, we did not plan to pool results of studies in meta‐analysis. </p> <p>Where a single trial reported multiple trial arms, we included only the relevant arms. If two comparisons (e.g. device A versus safe handling and device B versus safe handling) were combined in the same meta‐analysis, we planned to halve the control group to avoid double‐counting. </p> </section> <section id="CD012860-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ul id="CD012860-list-0008"> <li> <p>Study design: CBA studies versus other non‐randomised study designs; individual versus cluster unit of analysis. These were planned subgroup analyses. We also performed a post hoc subgroup analysis of uncontrolled before‐after studies versus cross‐sectional studies, as these were the two types of studies that contributed data for the analysis. This analysis can assess the impact of trend in improving safe handling practices that could be problematic in uncontrolled before‐after studies. </p> </li> <li> <p>Professional role: pharmacy technician versus chemotherapy nurse versus other healthcare staff. </p> </li> <li> <p>Duration of possible exposure.</p> </li> <li> <p>Intervention: any closed‐system drug‐transfer device.</p> </li> <li> <p>Control: safe handling following UK HSE standards.</p> </li> </ul> </p> <p>We planned to perform subgroup analyses for primary outcomes (i.e. immediate to short‐term contamination, short‐term health outcomes, long‐term reproductive health outcomes, and development of any type of cancers). We planned to use the Chi² test to test for subgroup interactions in Review Manager 5 (<a href="./references#CD012860-bbs2-0136" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD012860-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform a sensitivity analysis involving studies with low risk of bias versus studies with high risk of bias defined a priori to assess the robustness of our conclusions.  </p> <p>We performed a post hoc sensitivity analysis to assess the impact of the influence of different intracluster correlation coefficients on the results to determine if the differences in conclusions between our systematic review and primary research studies could be due to the lack of adjusting for cluster effect in primary research studies. </p> <section id="CD012860-sec-0046"> <h5 class="title">Summary of findings table</h5> <p>We created a 'Summary of findings' table using all outcomes (i.e. exposure, environmental contamination, health outcomes, adverse events, and potential cost savings). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012860-bbs2-0111" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), using GRADEpro software (<a href="./references#CD012860-bbs2-0106" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 22 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes. </p> <p>Since we described all the decisions to downgrade or upgrade the quality of studies using the footnotes and described the reason in detail under each outcome in the text, we did not compile an additional GRADE table showing all our decisions about the quality of evidence and their justifications. </p> </section> <section id="CD012860-sec-0047"> <h5 class="title">Reaching conclusions</h5> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided making recommendations for practice as these depend on additional considerations such as availability of resources, clinician values and preferences, among other context‐specific factors. Our implications for research suggest priorities for future research and outline what the remaining uncertainties are in the area. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012860-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012860-sec-0048"></div> <section id="CD012860-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD012860-sec-0050"> <h4 class="title">Results of the search</h4> <p>We identified a total of 9033 records from CENTRAL (70 references), MEDLINE (695 references), Embase (1043 references), OSH‐UPDATE (8 references), CINAHL (253 references), Science Citation Index Expanded (including Conference Proceedings) (6830 references), NHS EED (0 references), CEA at Tufts University (0 references), ClinicalTrials.gov (131 references), and the World Health Organization (WHO) trials portal (3 references). After excluding 1463 duplicate records and seeking 17 other references based on handsearching, we screened the titles and abstracts of 7587 records. We obtained full texts for 83 potentially eligible studies. Of these, we excluded 55 references for the reasons detailed in <a href="./references#CD012860-sec-0123" title="">Characteristics of excluded studies</a> and summarised in <a href="#CD012860-sec-0052">Excluded studies</a>. In total, we included 24 studies (28 references). See the study inclusion process explained in <a href="#CD012860-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012860-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram. CSTD: closed‐system transfer device" data-id="CD012860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram. <b>CSTD</b>: closed‐system transfer device </p> </div> </div> </div> </section> <section id="CD012860-sec-0051"> <h4 class="title">Included studies</h4> <p>All 24 included studies are cluster studies, that is, the comparison is between hospitals that used CSTD versus those that did not (cross‐sectional studies) or between the period in which CSTD was used versus the period in which it was not (interrupted time‐series or uncontrolled before‐after studies). Of the 24 included studies, 1 study (3 hospitals) is an interrupted time‐series (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>), 14 (66 hospitals) are uncontrolled before‐after studies (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>), and 9 (290 hospitals) are cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). In one cross‐sectional study, a hospital used the same isolators during the same period to prepare drugs using CSTD and no CSTD (<a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>). In another, the same hospital used two different isolators to prepare drugs over the same period: CSTD in one isolator and no CSTD in the other (<a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>). In the remaining seven cross‐sectional studies, 91 hospitals used CSTD and 197 hospitals did not (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). We did not find any randomised controlled trials or formal economic evaluations. Overall, 359 hospitals in Australia, Canada, France, Hungary, Italy, Japan, Malaysia, Turkey, UK, and the USA took part. Most hospitals were from Canada and the USA. There was also an overlap between hospitals included in the different studies, although there was minimal or no overlap in the period when the samples were collected (i.e. the samples were included only once in the analysis). </p> <p>In 22 studies, the people who used the intervention (CSTD plus safe handling) and control (safe handling alone) were pharmacists or pharmacy technicians (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>); in two studies, the people who used the intervention and control were nurses in addition to pharmacists or pharmacy technicians (<a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>). </p> <p>The CSTDs used in the studies were PhaSeal (13 studies: <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>), Tevadaptor (2 studies: <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>), SpikeSwan (1 study: <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>), PhaSeal and Tevadaptor (1 study: <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>), varied (5 studies: <a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>), and not stated (2 studies: <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). The descriptions of the control groups varied; although we provide the details reported in <a href="./references#CD012860-sec-0122" title="">Characteristics of included studies</a>, additional safety measures are likely to have been in place. </p> <p>The outcomes reported in the studies are exposure (4 studies: <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>), surface contamination (17 studies: <a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>), and potential cost savings (5 studies: <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>). None of the studies that report exposure reported the intracluster correlation coefficient. The remaining two studies did not report the outcomes in a format that could be tabulated or pooled with meta‐analysis, as key information was missing and we were unable to obtain it from study authors (<a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> <p>The duration of exposure of people to CSTD and control measures is relevant only for studies that reported the presence of hazardous drugs in urine (<a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). This was seven months in <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; not reported in <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; six months to CSTD without any information on the duration of exposure in the control group in <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; and two weeks in <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>. </p> <p>With regard to funding, eight studies received no special funding (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>, <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>, <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>, <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>), six studies received funding from manufacturers of the device being evaluated (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>), and the remaining ten studies did not report funding (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> </section> <section id="CD012860-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 55 studies after full‐text assessment (<a href="./references#CD012860-sec-0123" title="">Characteristics of excluded studies</a>). The main reasons for exclusion are as follows. </p> <p> <ul id="CD012860-list-0009"> <li> <p>Not a primary research study: eight studies (<a href="./references#CD012860-bbs2-0046" title="New needleless valves leading to spike in BSIs: solving one problem and creating another. Hospital Infection Control &amp; Prevention2005;32(7):89‐91. ">Hospital Infection Control 2005</a>; <a href="./references#CD012860-bbs2-0051" title="KunnevaL . Closed system drug transfer devices for chemotherapy. Nursing2016;46(1):67‐8. ">Kunneva 2016</a>; <a href="./references#CD012860-bbs2-0053" title="LawsJ . Checking the safety of closed system transfer devices. Occupational Health &amp; Safety2016;85(11):4. ">Laws 2016</a>; <a href="./references#CD012860-bbs2-0056" title="LennanE . Considering closed‐system transfer devices for safe handling of drugs. British Journal of Nursing2017;26(10):S26‐8. ">Lennan 2017</a>; <a href="./references#CD012860-bbs2-0060" title="MeadeE . Use of closed‐system drug transfer devices in the handling and administration of MABs. British Journal of Nursing2015;24(16 Suppl 1):S21‐7. ">Meade 2015</a>; <a href="./references#CD012860-bbs2-0066" title="Closed system drug transfer device reduces nurse exposure to hazardous drugs. Oncology Nurse Advisor2017;8(3):20‐1. ">Oncology Nurse Advisor 2017</a>; <a href="./references#CD012860-bbs2-0076" title="TalsmarJ . FDA warns against use of certain closed system transfer devices with Treanda injection. Drug Topics2015;10 April:36. ">Talsmar 2015</a>). </p> </li> <li> <p>Not a study comparing CSTD plus standard care versus standard care: 16 studies (<a href="./references#CD012860-bbs2-0028" title="ClarkBA , SessinkPJ . Use of a closed system drug‐transfer device eliminates surface contamination with antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(2):99‐104. ">Clark 2013</a>; <a href="./references#CD012860-bbs2-0029" title="ConnorTH , DeBordDG , PrettyJR , OliverMS , RothTS , LeesPS , et al. Evaluation of antineoplastic drug exposure of health care workers at three university‐based us cancer centers. Journal of Occupational and Environmental Medicine2010;52(10):1019‐27. ">Connor 2010</a>; <a href="./references#CD012860-bbs2-0030" title="ContractorS , ThomasJ , ShahidU . Use of the Phaseal transfer system during chemoembolization to prevent unintentional leakage of chemotherapeutic agents during preparation and delivery. Journal of Vascular and Interventional Radiology2015;26(5):e93. ">Contractor 2015</a>; <a href="./references#CD012860-bbs2-0031" title="CoxJ , SpeedV , O'NealS , HasselwanderT , SherwoodC , EckelSF , et al. Development and evaluation of a novel product to remove surface contamination of hazardous drugs. Journal of Oncology Pharmacy Practice2017;23(2):103‐15. ">Cox 2017</a>; <a href="./references#CD012860-bbs2-0035" title="Enciso‐ZarateA , Guzman‐OviedoJ , Sanchez‐CardonaF , Martinez‐RohenesD , Rodriguez‐PalominoJC , Alvarez‐RiscoA , et al. Evaluation of contamination by cytotoxic agents in Colombian hospitals. Pharmaceutical Care España2016;18(6):241‐50. ">Enciso‐Zarate 2016</a>; <a href="./references#CD012860-bbs2-0040" title='GillesL , FavierB , CatillonF , DussartC , PeyronF , SimoensX , et al. Improvement of quality of practices for the preparation of cytotoxic drugs: results of a "before‐after" study. Bulletin du Cancer2009;96(9):839‐49. '>Gilles 2009</a>; <a href="./references#CD012860-bbs2-0044" title="HongMY , LinYS , HwangYJ , LaiYH . Nurses' perceptions and satisfaction to the use of a closed‐system drug transfer device for chemotherapy administration. Oncology Nursing Forum2017;44(2 (2017 Oncology Nursing Society Annual Congress: Podium Abstracts)):182. ">Hong 2017</a>; <a href="./references#CD012860-bbs2-0047" title="IdellC , YostB , BearmanB , GallardoM . Strategies to increase staff compliance with use of closed‐system drug transfer devices (CSTD). Oncology Nursing Forum2009;36(3):75‐6. ">Idell 2009</a>; <a href="./references#CD012860-bbs2-0050" title="KoppB , SchierlR , NowakD . Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. International Archives of Occupational and Environmental Health2013;86(1):47‐55. ">Kopp 2013</a>; <a href="./references#CD012860-bbs2-0052" title="KuriharaT , UchidaT . Investigation in reduction of occupational exposures from anti‐cancer agents using the infusion set which incorporated bd Phasealtm system. Journal of Oncology Pharmacy Practice2017;23(4 Suppl):19‐20. ">Kurihara 2017</a>; <a href="./references#CD012860-bbs2-0062" title="NygrenO , GustavssonB , ErikssonR . A test method for assessment of spill and leakage from drug preparation systems. Annals of Occupational Hygiene2005;49(8):711‐8. ">Nygren 2005</a>; <a href="./references#CD012860-bbs2-0064" title="NymanHA , JorgensonJA , SlawsonMH . Workplace contamination with antineoplastic agents in a new cancer hospital using a closed‐system drug transfer device. Hospital Pharmacy2007;42(3):219‐25. ">Nyman 2007</a>; <a href="./references#CD012860-bbs2-0065" title="OdraskaP , DolezalovaL , KutaJ , OravecM , PilerP , BlahaL . Evaluation of the efficacy of additional measures introduced for the protection of healthcare personnel handling antineoplastic drugs. Annals of Occupational Hygiene2013;57(2):240‐50. ">Odraska 2013</a>; <a href="./references#CD012860-bbs2-0073" title="SessinkPJM , RolfMAE , RydenNS . Evaluation of the Phaseal hazardous drug containment system. Hospital Pharmacy1999;34(11):1311‐7. ">Sessink 1999</a>; <a href="./references#CD012860-bbs2-0078" title="TylerTG , PowerLA . Assessment of a new closed system drug‐transfer device (CSTD) at 13 U.S. cancer centers. Journal of Oncology Pharmacy Practice2017;23(4 Suppl):21. ">Tyler 2017</a>; <a href="./references#CD012860-bbs2-0079" title="YoshidaJ , KodaS , NishidaS , NakanoH , TeiG , KumagaiS . Association between occupational exposure and control measures for antineoplastic drugs in a pharmacy of a hospital. Annals of Occupational Hygiene2013;57(2):251‐60. ">Yoshida 2013</a>). This reason encompasses studies that introduced other safety measures such as biosafety cabinets or change in the layout of the pharmacy in addition to CSTD as well as studies that cleaned the surfaces for only the CSTD group prior to exposure to hazardous drugs, which clearly does not estimate the benefits or harms of CSTD plus safe handling versus safe handling alone. </p> </li> <li> <p>Simulation study: 28 studies (<a href="./references#CD012860-bbs2-0026" title="BlazawskiJ , DeFreitasE . Testing the sterility of single‐use vials of bevacizumab and cetuximab after entry with the Phaseal closed‐system transfer device. Journal of the American Pharmacists Association2013;53(5):e164. ">Blazawski 2013</a>; <a href="./references#CD012860-bbs2-0027" title="ChantryA , Fanton d'AndonC , GouilletA , GarrigueP , GuilletB . A specific fluorescein‐combined media fill test for validation of aseptic radiopharmaceutical preparations and assessment of good radiopharmacy practice. European Journal of Nuclear Medicine and Molecular Imaging2015;42(Suppl 1):S484. ">Chantry 2015</a>; <a href="./references#CD012860-bbs2-0032" title="DeAusenL , DeFreitasEF , LittletonL , LustikM . Leakage from closed‐system transfer devices as detected by a radioactive tracer. American Journal of Health‐System Pharmacy2013;70(7):619‐23. ">De Ausen 2013</a>; <a href="./references#CD012860-bbs2-0034" title="DePrijckK , D'HaeseE , VandenbrouckeJ , CouckeW , RobaysH , NelisHJ . Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Letters in Applied Microbiology2008;47(6):543‐8. ">De Prijck 2008</a>; <a href="./references#CD012860-bbs2-0033" title="DeFreitasE . Comparison of closed systems drug transfer devices (CSTDs) using technetium (Tc99m) as a radioactive tracer. Journal of Oncology Pharmacy Practice2012;18(2 Suppl):11‐2. ">DeFreitas 2012</a>; <a href="./references#CD012860-bbs2-0036" title="FavierB , LabrosseH , Gilles‐AfchainL , CropetC , PerolD , ChaumardN , et al. The Phaseal® system: impact of its use on workplace contamination and duration of chemotherapy preparation. Journal of Oncology Pharmacy Practice2012;18(1):37‐45. ">Favier 2012</a>; <a href="./references#CD012860-bbs2-0037" title="FernandezJSR , DelCarmen Lozano IglesiasM , PeinadoII . Microbiological stability of drugs elaborated in a biological safety cabinet using a closed‐system drug transfer device. Anales de la Real Academia Nacional de Farmacia2013;79(3):465‐80. ">Fernandez 2013</a>; <a href="./references#CD012860-bbs2-0038" title="GarrigueP , MontanaM , VentreC , SavryA , Gauthier‐VillanoL , PisanoP , et al. Safe cytotoxic drug preparation using closed‐system transfer device: Technical and practical evaluation of a new device (Vialshield/Texium) comparatively to a reference one (Phaseal). International Journal of Pharmaceutical Compound2016;20(2):148‐54. ">Garrigue 2016</a>; <a href="./references#CD012860-bbs2-0039" title="GebelJ . Evaluation of the microbial tightness of closed system transfer devices by simulating airborne and touch contamination. Critical Care2015;19(Suppl 1):S29‐30. ">Gebel 2015</a>; <a href="./references#CD012860-bbs2-0041" title="Gomez‐AlvarezS , Porta‐OltraB , Hernandez‐GrisoM , Perez‐LabanaF , Climente‐MartiM . Evaluation of two closed‐system drug transfer device in the antineoplastic drug elaboration process. Farmacia Hospitalaria2016;40(1):36‐43. ">Gomez‐Alvarez 2016</a>; <a href="./references#CD012860-bbs2-0042" title="Gonzalez‐Haba PenaE , Manrique RodriguezS , Herranz AlonsoAM , Perez CastanP , Moreno GalvezM , Iglesias PeinadoI , et al. Comparative study of preparation of hazardous drugs with different closed‐system drug transfer devices by means of simulation with fluorescein. Farmacia Hospitalaria2016;40(n06):496‐503. ">Gonzalez‐Haba Pena 2016</a>; <a href="./references#CD012860-bbs2-0043" title="HamaK , KitadaN , FukushimaK , HashidaT , KataokaK . Investigation on residual‐related error and the effect of solution properties using protective devices for the reconstitution of cytotoxic agents in actual situations. Journal of Oncology Pharmacy Practice2011;17(1):55‐60. ">Hama 2011</a>; <a href="./references#CD012860-bbs2-0048" title="IkenoY , AriiD , NakajimaH , MurookaK , NojimaM , KidokoroA . Verification of reduction in preparation time and cost of cyclophosphamide when using the closed‐system drug transfer device. Gan to Kagaku Ryoho2014;41(5):611‐5. ">Ikeno 2014</a>; <a href="./references#CD012860-bbs2-0049" title="JorgensonJA , SpiveySM , AuC , CanannD , RitterH , SmithB . Contamination comparison of transfer devices intended for handling hazardous drugs. Hospital Pharmacy2008;43(9):723‐7. ">Jorgenson 2008</a>; <a href="./references#CD012860-bbs2-0055" title="LeGarlantezecP , Rizzo‐PadoinN , AupeeO , LamandV , BrotoH , AlmerasD . Evaluation of the performance of transfer devices in a closed system using a radioactive solution of [99mTC] [Évaluation de la performance de dispositifs de transfert en système clos au moyen d'une solution radioactive de [99mTC]]. Annales Pharmaceutiques Françaises2011;69(3):182‐91. ">Le Garlantezec 2011</a>; <a href="./references#CD012860-bbs2-0057" title="LinC , ChiangSC . Challenge the compatibility of closed system transfer devices with multiple chemotherapy drugs. Journal of Oncology Pharmacy Practice2017;23(4 Suppl):3. ">Lin 2017</a>; <a href="./references#CD012860-bbs2-0059" title="McMichaelDM , JeffersonDM , CareyET , ForreyRA , SpiveySM , MulvaneyJM , et al. Utility of the Phaseal closed system drug transfer device. American Journal of Pharmacy Benefits2011;3(1):9‐16. ">McMichael 2011</a>; <a href="./references#CD012860-bbs2-0061" title="NishigakiR , KonnoE , SugiyasuM , YonemuraM , OtsukaT , WatanabeY , et al. The usefulness of a closed‐system device for the mixing of injections to prevent occupational exposure to anticancer drugs. Journal of Japanese Society of Hospital Pharmacists2010;46(1):113‐7. ">Nishigaki 2010</a>; <a href="./references#CD012860-bbs2-0063" title="NygrenO , OlofssonE , JohanssonL . Spill and leakage using a drug preparation system based on double‐filter technology. Annals of Occupational Hygiene2008;52(2):95‐8. ">Nygren 2008</a>; <a href="./references#CD012860-bbs2-0067" title="PerloG , DavitA , VigliettiAL , BiggiA . Use of needle free closed system devices in the radio labelled white blood cells (wbc) procedure. Clinical and Translational Imaging2015;3(Suppl 1):S131. ">Perlo 2015</a>; <a href="./references#CD012860-bbs2-0068" title="Queruau LamerieT , CarrezL , DecaudinB , BouchoudL , GoossensJF , BarthelemyC , et al. Multiple‐test assessment of devices to protect healthcare workers when administering cytotoxic drugs to patients. Journal of Oncology Pharmacy Practice2012;18(2):191‐200. ">Queruau Lamerie 2012</a>; <a href="./references#CD012860-bbs2-0069" title="RuppK , TylerT . Assessment of a new closed system drug‐transfer device at 17 us cancer centers. Oncology Nursing Forum2017;44(2 (2017 Oncology Nursing Society Annual Congress: Podium Abstracts)):29. ">Rupp 2017</a>; <a href="./references#CD012860-bbs2-0070" title="Sanchez‐Rubio FerrandezJ , Lozano EstebanMC , Iglesias PeinadoI , Fernandez AlonsoJM , Bautista SanzMP , Matilla GarciaE , et al. Microbiological stability of vials used in cytostatic compounding. European Journal of Hospital Pharmacy: Science and Practice2012;19(2):144‐5. ">Sanchez‐Rubio Ferrandez 2012</a>; <a href="./references#CD012860-bbs2-0070" title="Sanchez‐Rubio FerrandezJ , Lozano EstebanMC , Iglesias PeinadoI , Fernandez AlonsoJM , Bautista SanzMP , Matilla GarciaE , et al. Microbiological stability of vials used in cytostatic compounding. European Journal of Hospital Pharmacy: Science and Practice2012;19(2):144‐5. ">Sanchez‐Rubio Ferrandez 2012</a>; <a href="./references#CD012860-bbs2-0072" title="SatoJ , OdagiriN , TeruiK , IwasakiY , HosoyaE , HayakariM . Availability evaluation of closed systems by using practical training kits for preparation of antitumor drugs. Japanese Journal of Cancer and Chemotherapy2010;37(9):1753‐7. ">Sato 2010</a>; <a href="./references#CD012860-bbs2-0074" title="SimonN , DecaudinB , LannoyD , DanicourtF , BarthelemyC , OdouP . Technical evaluation of a new sterile medical device to improve anticancer chemotherapy administration. Oncology Nursing Forum2010;37(6):E370‐6. ">Simon 2010</a>; <a href="./references#CD012860-bbs2-0075" title="SmithST , SzlaczkyMC . Syringe plunger contamination by hazardous drugs: a comparative study. Journal of Oncology Pharmacy Practice2014;20(5):381‐5. ">Smith 2014</a>; <a href="./references#CD012860-bbs2-0077" title="Thomas CareyE , ForreyRA , HaughsD , JeffersonDM , JorgensonJA , McMichaelDM , et al. Second look at utilization of a closed‐system transfer device (Phaseal). American Journal of Pharmacy Benefits2011;3(6):311‐8. ">Thomas Carey 2011</a>). </p> </li> <li> <p>Comparison of different CSTDs: two studies (<a href="./references#CD012860-bbs2-0025" title="AmosC . A human factors usability comparison of three closed drug‐transfer systems. Journal of Oncology Pharmacy Practice2012;18:18‐9. ">Amos 2012</a>; <a href="./references#CD012860-bbs2-0054" title="LedfordA , MaliakalP , RogersT , MackeyM . Evaluation of two closed system transfer devices in an outpatient community cancer center. Journal of Oncology Pharmacy Practice2010;16(1 Suppl):16‐7. ">Ledford 2010</a>). </p> </li> <li> <p>Intermittent use of CSTD (not possible to determine whether the outcomes were for CSTD or standard care): one study (<a href="./references#CD012860-bbs2-0058" title="McDiarmidMA , OliverMS , RothTS , RogersB , EscalanteC . Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. Journal of Occupational and Environmental Medicine2010;52(10):1028‐34. ">McDiarmid 2010</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012860-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias in the included studies is summarised in <a href="#CD012860-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012860-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green +: Low risk of bias. Yellow ?: Moderate risk of bias or 'No information'. Red ‐: Serious or critical risk of bias." data-id="CD012860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green +: Low risk of bias. Yellow ?: Moderate risk of bias or 'No information'. Red ‐: Serious or critical risk of bias. </p> </div> </div> </div> <section id="CD012860-sec-0054"> <h4 class="title">Confounding bias</h4> <p>There is insufficient information to assess the risk of confounding bias in all the studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). This is because none of the studies reported whether there were any baseline differences in any of the confounding factors. </p> </section> <section id="CD012860-sec-0055"> <h4 class="title">Selection bias</h4> <p>Fourteen studies are at low risk of selection bias (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). Nine studies are at moderate risk of selection bias, as the participating centres were probably selected or returned the questionnaire about CSTD use based on their safe handling practices (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). One study is at serious risk of bias as the sites of sampling differed between CSTD and control groups (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>). None of the studies are at critical risk of bias. </p> </section> <section id="CD012860-sec-0056"> <h4 class="title">Bias in classification of interventions</h4> <p>All the studies are at low risk of bias since the classification of CSTD versus control was made clearly (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> </section> <section id="CD012860-sec-0057"> <h4 class="title">Bias due to deviations from intended interventions</h4> <p>There is insufficient information to assess the risk of bias due to deviations from intended interventions in 16 studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>), as they did not report whether the training periods and other co‐interventions were similar in both groups. The remaining eight studies are at serious risk of bias, since it is clear that only CSTD groups received additional training while the control group did not receive an equivalent period of training in safe handling (<a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). </p> </section> <section id="CD012860-sec-0058"> <h4 class="title">Bias due to missing data</h4> <p>Eighteen studies are at low risk of bias due to missing data (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). There is insufficient information to assess the risk of bias in the remaining six studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>), as there is either missing information, the impact of which on the effect estimates is not clear, or it is not clear whether there is missing information in the studies. </p> </section> <section id="CD012860-sec-0059"> <h4 class="title">Bias in measurement of outcomes</h4> <p>All 24 studies are at serious risk of bias in measurement of outcomes as it appears that none of the studies used blinded assessment of outcomes (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> </section> <section id="CD012860-sec-0060"> <h4 class="title">Bias in selection of the reported result</h4> <p>Six studies are at low risk of bias in selection of the reported result (<a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). The remaining 18 studies are at serious risk of bias in selection of the reported result: they report results partially (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> </section> <section id="CD012860-sec-0061"> <h4 class="title">Overall risk of bias</h4> <p>All the studies are at serious risk of bias (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). </p> </section> </section> <section id="CD012860-sec-0062"> <h3 class="title" id="CD012860-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD012860-tbl-0001"><b>Summary of findings for the main comparison</b> Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and surface contamination</a>; <a href="./full#CD012860-tbl-0002"><b>Summary of findings 2</b> Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</a> </p> <p>The raw data used for analysis are available in <a href="./appendices#CD012860-sec-0106">Appendix 9</a> and <a href="./appendices#CD012860-sec-0107">Appendix 10</a>. </p> <section id="CD012860-sec-0063"> <h4 class="title">Primary outcomes</h4> <section id="CD012860-sec-0064"> <h5 class="title">Exposure</h5> <section id="CD012860-sec-0065"> <h6 class="title">Presence of hazardous drugs in urine</h6> <p>Four studies (seven hospitals; 70 participants) report the proportion of people with positive urine tests for exposure (<a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). One study is a cross‐sectional study involving four hospitals (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). The other studies are uncontrolled before‐after studies, each involving a single hospital (<a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). The drugs measured in these trials are cyclophosphamide alone in two studies (<a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>), cyclophosphamide or ifosfamide in one study (<a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>), and cyclophosphamide, ifosfamide, or gemcitabine in one study (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). There are no considerable differences in the proportion of people with positive urine tests for exposure between the CSTD and control groups for cyclophosphamide alone (RR 0.83, 95% CI 0.46 to 1.52; I² = 0%; 2 studies; 2 hospitals; 20 participants); cyclophosphamide or ifosfamide (RR 0.09, 95% CI 0.00 to 2.79;1 study; 1 hospital; 14 participants); and cyclophosphamide, ifosfamide, or gemcitabine (RR not estimable; 1 study; 4 hospitals; 36 participants) (<a href="./references#CD012860-fig-0005" title="">Analysis 1.1</a>). There is no alteration in the interpretation of results using the fixed‐effect or the random‐effects model. </p> <p>Quality of evidence: the quality of evidence is very low because of the serious risk of bias in the studies (downgraded by one level), imprecision (small sample size (downgraded by one level) and wide confidence intervals (downgraded by one level)). </p> <p>Subgroup analysis: since there is only one cross‐sectional study and this is the only study examining cyclophosphamide, ifosfamide, or gemcitabine, we did not perform a subgroup analysis of uncontrolled before‐after studies versus cross‐sectional studies. PhaSeal was used in three studies (<a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). The authors of the fourth study did not report which device they used (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). There were no considerable differences in the proportion of people with positive urine tests for exposure between the PhaSeal and control groups (<a href="./references#CD012860-fig-0008" title="">Analysis 2.1</a>). </p> <p>Sensitivity analysis: There is also no alteration in the interpretation of results using different intracluster correlation coefficients (ICC) (<a href="./references#CD012860-fig-0021" title="">Analysis 3.1</a>; <a href="./references#CD012860-fig-0022" title="">Analysis 3.2</a>; <a href="./references#CD012860-fig-0023" title="">Analysis 3.3</a>). </p> </section> <section id="CD012860-sec-0066"> <h6 class="title">Other measures of exposure</h6> <p>None of the studies reported on blood tests or other measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, or micronuclei induction. </p> </section> <section id="CD012860-sec-0067"> <h6 class="title">Environmental contamination</h6> <section id="CD012860-sec-0068"> <p><b>Proportion of surfaces contaminated in pharmacy areas</b></p> <p>Fifteen studies (343 hospitals, 3156 surface samples) report the proportion of surface samples that were contaminated with various drugs in the pharmacy areas (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). Seven are cross‐sectional studies involving 284 hospitals (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>), and eight are uncontrolled before‐after studies involving 59 hospitals (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). There are no considerable differences in the proportion of surface samples that were contaminated between the CSTD and the control groups for any of the drugs in the pharmacy areas except 5‐fluorouracil (<a href="./references#CD012860-fig-0006" title="">Analysis 1.2</a>). </p> <p> <ul id="CD012860-list-0010"> <li> <p>Cyclophosphamide: RR 0.89, 95% CI 0.78 to 1.01; I² = 35% (13 studies: 7 uncontrolled before‐after studies (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>); 6 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 338 hospitals, 2937 surface samples). </p> </li> <li> <p>Ifosfamide: RR 0.94, 95% CI 0.74 to 1.19; I² = 8% (9 studies: 3 uncontrolled before‐after studies (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>); 6 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 304 hospitals, 2332 surface samples). </p> </li> <li> <p>Methotrexate: RR 0.84, 95% CI 0.58 to 1.22; I² = 0% (6 studies: 1 uncontrolled before‐after study (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>); 5 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>); 280 hospitals, 1781 surface samples). </p> </li> <li> <p>5‐fluorouracil: RR 0.63, 95% CI 0.42 to 0.94; I² = 0% (4 studies: 2 uncontrolled before‐after study (<a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>); 2 cross‐sectional studies (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 107 hospitals, 1068 surface samples). </p> </li> <li> <p>Cytarabine: RR 0.72, 95% CI 0.18 to 2.86; I² = 43% (2 studies: all cross‐sectional studies (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 84 hospitals, 780 surface samples). </p> </li> <li> <p>Gemcitabine: RR 0.96, 95% CI 0.60 to 1.54; I² = 0% (2 cross‐sectional studies (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 84 hospitals, 780 surface samples). </p> </li> <li> <p>Irinotecan: RR 0.36, 95% CI 0.10 to 1.33 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 493 surface samples). </p> </li> <li> <p>Docetaxel: not estimable (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 493 surface samples). </p> </li> <li> <p>Paclitaxel: RR 0.57, 95% CI 0.04 to 9.06 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 493 surface samples). </p> </li> <li> <p>Vinorelbine: RR 1.72, 95% CI 0.16 to 18.73 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 493 surface samples). </p> </li> <li> <p>Ganciclovir: RR 0.01, 95% CI 0.00 to 27.11 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>); 1 hospital, 287 surface samples). </p> </li> <li> <p>Epirubicin: RR 0.03, 95% CI 0.00 to 6.29 (1 uncontrolled before‐after study (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>); 1 hospital, 60 surface samples). </p> </li> <li> <p>Multiple drugs (data on each drug were not available): RR 0.87, 95% CI 0.43 to 1.77 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>); 4 hospitals, 109 surface samples). </p> </li> </ul> </p> <p>There is no alteration in the interpretation of results using the fixed‐effect or the random‐effects model. </p> <p>Quality of evidence: the quality of evidence is very low because of the serious risk of bias in all the studies (downgraded by one level); indirectness of the outcome, as all the outcomes reported are surrogate outcomes (downgraded by one level); and imprecision because of wide confidence intervals (downgraded by one level) or lack of evidence that the observed difference led to decreased exposure or tangible short‐term or long‐term health outcomes (downgraded by one level). </p> <p>Subgroup analysis: there is no evidence of subgroup differences in the analyses that could be stratified by study design (uncontrolled before‐after versus cross‐sectional studies) (<a href="./references#CD012860-fig-0009" title="">Analysis 2.2</a>; <a href="./references#CD012860-fig-0010" title="">Analysis 2.3</a>; <a href="./references#CD012860-fig-0011" title="">Analysis 2.4</a>; <a href="./references#CD012860-fig-0012" title="">Analysis 2.5</a>). The device used in eight studies was PhaSeal (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0023" title="YoshidaJ , TeiG , MochizukiC , MasuY , KodaS , KumagaiS . Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene2009;53(2):153‐60. ">Yoshida 2009</a>). The devices used in five studies were variable (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>). The device used in one study was Tevadaptor (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). The last study did not report the device used in the study (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). There is no evidence of difference in proportion of surface samples that were contaminated between the PhaSeal and the control groups for any of the drugs other than cyclophosphamide (RR 0.88, 95% CI 0.78 to 0.99; 8 studies; 59 hospitals, 1278 surface samples; <a href="./references#CD012860-fig-0013" title="">Analysis 2.6</a>). There is no evidence of difference in proportion of surface samples that were contaminated between the Tevadaptor and the control groups for any of the drugs (<a href="./references#CD012860-fig-0014" title="">Analysis 2.7</a>) </p> <p>Sensitivity analysis: there is also no alteration in the interpretation of results using different ICCs except for cyclophosphamide for intracluster coefficients of 0.05, 0.01, and 0.00, and for ganciclovir and epirubicin for ICCs of 0.01 and 0.00 (<a href="./references#CD012860-fig-0024" title="">Analysis 3.4</a>; <a href="./references#CD012860-fig-0025" title="">Analysis 3.5</a>; <a href="./references#CD012860-fig-0026" title="">Analysis 3.6</a>). </p> </section> <section id="CD012860-sec-0069"> <p><b>Proportion of surfaces contaminated in patient‐care areas</b></p> <p>Six studies (283 hospitals, 1568 surface samples) reported the proportion of surface samples that were contaminated with various drugs in the patient‐care areas (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). There were no considerable differences in the proportion of surface samples that were contaminated with various drugs in the patient‐care areas between the CSTD and control groups in the patient‐care areas (<a href="./references#CD012860-fig-0006" title="">Analysis 1.2</a>). </p> <p> <ul id="CD012860-list-0011"> <li> <p>Cyclophosphamide: RR 1.01, 95% CI 0.86 to 1.18; I² = 0% (5 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>); 279 hospitals, 1535 surface samples). </p> </li> <li> <p>Ifosfamide: RR 1.44, 95% CI 0.91 to 2.28; I² = 20% (5 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>); 279 hospitals, 1535 surface samples). </p> </li> <li> <p>Methotrexate: RR 1.00, 95% CI 0.55 to 1.85; I² = 0% (5 cross‐sectional studies (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>); 279 hospitals, 1535 surface samples). </p> </li> <li> <p>5‐fluorouracil: RR 1.09, 95% CI 0.53 to 2.23 (1cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Cytarabine: RR 0.59, 95% CI 0.01 to 24.53 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Gemcitabine: RR 1.13, 95% CI 0.55 to 2.33 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Irinotecan: RR 0.44, 95% CI 0.03 to 6.15 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Docetaxel: RR 0.59, 95% CI 0.01 to 24.53 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Paclitaxel: RR 0.59, 95% CI 0.01 to 24.53 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Vinorelbine: RR not estimable (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>); 83 hospitals, 460 surface samples). </p> </li> <li> <p>Multiple drugs (data on each drug were not available): RR 2.38, 95% CI 0.69 to 8.23 (1 cross‐sectional study (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>); 4 hospitals, 33 surface samples). </p> </li> </ul> </p> <p>Quality of evidence: the quality of evidence is very low because of the serious risk of bias in all the studies (downgraded by one level); indirectness, as all the reported outcomes are surrogate outcomes (downgraded by one level); and imprecision, as the confidence intervals are wide (downgraded by one level). </p> <p>Subgroup analysis: all the analyses stratified by the drug measured in the samples included either uncontrolled before‐after studies or cross‐sectional studies. Therefore, a subgroup analysis based on study design is not possible. The devices used in five studies varied (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>), while one study did not report it (<a href="./references#CD012860-bbs2-0020" title="SottaniC , PorroB , ImbrianiM , MinoiaC . Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters2012;213(1):107‐15. ">Sottani 2012</a>). </p> <p>Sensitivity analysis: there is also no alteration in the interpretation of results using ICCs of 0.05, 0.01, or 0.00 (<a href="./references#CD012860-fig-0024" title="">Analysis 3.4</a>; <a href="./references#CD012860-fig-0024" title="">Analysis 3.4</a>; <a href="./references#CD012860-fig-0025" title="">Analysis 3.5</a>). </p> </section> <section id="CD012860-sec-0070"> <p><b>Quantity of contamination in surface samples from pharmacy areas</b></p> <p>Seven studies (282 hospitals, 1793 surface samples) report the quantity of contamination with cyclophosphamide from surface samples in pharmacy areas (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>). Five are cross‐sectional studies involving 279 hospitals using various types of CSTD (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>), and two are uncontrolled before‐after studies involving three hospitals using PhaSeal (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>). The amount of cyclophosphamide is lower in pharmacy areas between the CSTD group and the control group (MD −49.34 pg/cm², 95% CI −84.11 to −14.56, I² = 0%; <a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). There is no alteration in the interpretation of results using the fixed‐effect or the random‐effects model. </p> <p>In addition, one interrupted time‐series study (3 hospitals; 342 samples) provides data on the quantity of contamination with cyclophosphamide from surface samples in pharmacy areas during three, three‐week phases: initial phase of no CSTD, followed by CSTD, and then by no CSTD (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>). Investigators took biweekly measurements in all three phases. Between the first two phases, the change in the slope between pre‐CSTD and CSTD was 3.9439 pg/cm² (95% CI 1.2303 to 6.6576; P = 0.01). Between the second and third phases, the slope and level were expected to rise again, but the change in the slope between CSTD and post‐CSTD withdrawal was −1.9331 pg/cm² (95% CI −5.126 to 1.2598; P = 0.200), and the level was 14.1670 pg/cm² (SD = 10.6190). </p> <p>Six studies (280 hospitals, 1749 surface samples) report the quantity of contamination with ifosfamide and methotrexate from surface samples in pharmacy areas (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>). Five studies are cross‐sectional studies involving 279 hospitals using various types of CSTD (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>), and one study is an uncontrolled before‐after study involving one hospital using PhaSeal (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>). There are no considerable differences in the amount of ifosfamide and methotrexate in pharmacy areas between the CSTD group and the control group (MD −0.32 pg/cm², 95% CI −6.58 to 5.94, I² = 11% and MD −3.09 pg/cm², 95% CI −13.80 to 7.61, I² = 0%, respectively; <a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). There is no alteration in the interpretation of results using the fixed‐effect or the random‐effects model. </p> <p>Three studies (85 hospitals, 602 surface samples) report the quantity of contamination with 5‐fluorouracil (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>; <a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). Two were cross‐sectional studies (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>), while the third one was an uncontrolled before‐after study (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). One study used variable CSTD (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>), one study used Spike Swan (<a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>), and the last study used Tevadaptor (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). There are no considerable differences in the amount of 5‐fluorouracil in pharmacy areas between the CSTD group and the control group ((MD 231.62 pg/cm², 95% CI −460.52 to 923.76). </p> <p>One study (83 hospitals, 493 surface samples) reports the quantity of contamination with cytarabine, gemcitabine, and irinotecan from surface samples in pharmacy areas (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>). This is a cross‐sectional study involving 83 hospitals using various types of CSTD (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>). There are no considerable differences in the amount of cytarabine, gemcitabine, and irinotecan in pharmacy areas between the CSTD group and the control group (cytarabine: MD −0.60 pg/cm², 95% CI −15.67 to 14.47; gemcitabine: MD −32.70 pg/cm², 95% CI −102.43 to 37.03; and irinotecan: MD −18.27 pg/cm², 95% CI −56.89 to 20.35; <a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). </p> <p>One study (1 hospital, 60 surface samples) reports the quantity of contamination with epirubicin from surface samples in pharmacy areas (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). The amount of epirubicin is lower in pharmacy areas between the CSTD group and the control group (MD −110.00 pg/cm², 95% CI −112.93 to −107.07) (<a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). </p> <p>Quality of evidence: the quality of evidence is very low because of the serious risk of bias in all the studies (downgraded by one level); indirectness, as all the reported outcomes are surrogate outcomes (downgraded by one level); and imprecision, as the confidence intervals are wide (downgraded by one level) or there is no evidence that the observed difference led to decreased exposure or tangible short‐term or long‐term health outcomes (downgraded by one level). </p> <p>Subgroup analysis: there is no evidence of subgroup differences based on study design for the drugs for which we could perform subgroup analyses (<a href="./references#CD012860-fig-0015" title="">Analysis 2.8</a>; <a href="./references#CD012860-fig-0016" title="">Analysis 2.9</a>; <a href="./references#CD012860-fig-0017" title="">Analysis 2.10</a>; <a href="./references#CD012860-fig-0019" title="">Analysis 2.12</a>). Two studies used PhaSeal (<a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>), one study used Spike Swan (<a href="./references#CD012860-bbs2-0005" title="ForgesF , SimoensX , ChauvinF . Comparative parallel assessment of a transfer device in reducing 5‐fluorouracil environmental contamination inside positive air pressure isolators. Journal of Oncology Pharmacy Practice2011;17(1):61‐7. ">Forges 2011</a>), and one study used Tevadaptor (<a href="./references#CD012860-bbs2-0021" title="VyasN , TurnerA , ClarkJM , SewellGJ . Evaluation of a closed‐system cytotoxic transfer device in a pharmaceutical isolator. Journal of Oncology Pharmacy Practice2016;22(1):10‐9. ">Vyas 2016</a>). We could perform tests for subgroup differences for 5‐fluorouracil only as there is no comparison using two different types of CSTD for the remaining comparisons. There is no evidence of subgroup differences based on device for 5‐fluorouracil. Only one study reports the use of a single type of CSTD (PhaSeal) before measuring ifosfamide and methotrexate in pharmacy areas. There is no evidence of difference in the amount of ifosfamide and methotrexate between PhaSeal and control groups (ifosfamide: MD −2.59 pg/cm², 95% CI −26.75 to 21.57; and methotrexate: MD 10.34 pg/cm², 95% CI −34.01 to 54.69; <a href="./references#CD012860-bbs2-0006" title="GuillemetteA , LangloisH , VoisineM , MergerD , TherrienR , MercierG , et al. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: the centralization of the priming of IV tubing in the pharmacy and use of a closed‐system transfer device. Journal of Oncology Pharmacy Practice2014;20(6):426‐32. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Guillemette 2014</a>; <a href="./references#CD012860-fig-0018" title="">Analysis 2.11</a>). All the studies that measured the quantity of contamination in patient‐care areas used varied CSTDs, so we could not perform a subgroup analysis based on device. </p> <p>Sensitivity analysis: there is also no alteration in the interpretation of results using ICCs of 0.05, 0.01, and 0.00 (<a href="./references#CD012860-fig-0027" title="">Analysis 3.7</a>; <a href="./references#CD012860-fig-0028" title="">Analysis 3.8</a>; <a href="./references#CD012860-fig-0029" title="">Analysis 3.9</a>). </p> </section> <section id="CD012860-sec-0071"> <p><b>Quantity of contamination in surface samples from patient‐care areas</b></p> <p>Five studies (279 hospitals, 1535 surface samples) report the quantity of contamination from surface samples in different drugs (cyclophosphamide, ifosfamide, and methotrexate) in patient‐care areas (<a href="./references#CD012860-bbs2-0001" title="BerruyerM , TanguayC , CaronNJ , LefebvreM , BussieresJF . Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: A 2013 follow‐up study. Journal of Occupational and Environmental Hygiene2015;12(2):87‐94. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Berruyer 2015</a>; <a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>; <a href="./references#CD012860-bbs2-0009" title="JanesA , TanguayC , CaronNJ , BussieresJF . Environmental contamination with cyclophosphamide, ifosfamide, and methotrexate: a study of 51 Canadian centres. Canadian Journal of Hospital Pharmacy2015;68(4):279‐89. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Janes 2015</a>; <a href="./references#CD012860-bbs2-0014" title="PoupeauC , TanguayC , CaronNJ , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals. Journal of Oncology Pharmacy Practice2018;24(1):9‐17. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Poupeau 2016</a>; <a href="./references#CD012860-bbs2-0015" title="RolandC , CaronN , BussieresJF . Multicenter study of environmental contamination with cyclophosphamide, ifosfamide and methotrexate in 66 Canadian hospitals: a 2016 follow‐up study. Journal of Occupational and Environmental Hygiene2017;14(8):661‐9. TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Roland 2017</a>). All studies have a cross‐sectional design and used various types of CSTD. There are no considerable differences in the amount of cyclophosphamide, ifosfamide, and methotrexate in patient‐care areas between CSTD group and the control group (cyclophosphamide: MD −13.34 pg/cm², 95% CI −36.01 to 9.32, I² = 0%; ifosfamide: MD 3.59 pg/cm², 95% CI −3.45 to 10.63, I² = 0%; and methotrexate: MD 0.10 pg/cm², 95% CI −0.57 to 0.78, I² = 0%) (<a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). </p> <p>One cross‐sectional study (83 hospitals, 460 surface samples) using various types of CSTD reports the quantity of contamination with 5‐fluorouracil, cytarabine, gemcitabine, and irinotecan from surface samples in patient‐care areas (<a href="./references#CD012860-bbs2-0003" title="ChauchatL , TanguayC , CaronN , GagnéS , LabrècheF , BussièresJF . Multicenter study of the surface contamination with ten antineoplastics in 81 Canadian hospitals in 2017. www.gerpac.eu/multicenter‐study‐of‐the‐surface‐contamination‐with‐ten‐antineoplastics‐in‐81‐canadian‐hospitals‐in‐2017 (accessed on 29 November 2017). TanguayC , BussieresJF . Additional information on study methods and data related to study. Bussieres JFAugust 2017. ">Chauchat 2017</a>). There are no considerable differences in the amount of 5‐fluorouracil, cytarabine, gemcitabine, and irinotecan in patient‐care areas between CSTD group and the control group (5‐fluorouracil: MD −43.90 pg/cm², 95% CI −141.51 to 53.71; cytarabine: MD −0.20 pg/cm², 95% CI −0.79 to 0.39; gemcitabine: MD 0.47 pg/cm², 95% CI −1.77 to 2.71; and irinotecan: MD −0.05 pg/cm², 95% CI −0.15 to 0.05; <a href="./references#CD012860-fig-0007" title="">Analysis 1.3</a>). </p> <p>Quality of evidence: the quality of evidence is very low because of the serious risk of bias in all the studies (downgraded by one level); indirectness, as all the outcomes reported are surrogate outcomes (downgraded by one level); and imprecision, as the confidence intervals are wide (downgraded by one level). In addition, there is evidence of publication bias for the quantity of cyclophosphamide in patient areas (downgraded by one level). </p> <p>Subgroup analysis: all studies used various types of CSTD.</p> <p>Sensitivity analysis: there is also no alteration in the interpretation of results using ICCs of 0.05, 0.01, and 0.00 (<a href="./references#CD012860-fig-0027" title="">Analysis 3.7</a>; <a href="./references#CD012860-fig-0028" title="">Analysis 3.8</a>; <a href="./references#CD012860-fig-0029" title="">Analysis 3.9</a>). </p> </section> <section id="CD012860-sec-0072"> <p><b>Atmospheric contamination</b></p> <p>None of the studies report atmospheric contamination.</p> </section> </section> </section> <section id="CD012860-sec-0073"> <h5 class="title">Short‐term health outcomes</h5> <p>None of the studies report short‐term health outcomes such as skin rashes.</p> </section> <section id="CD012860-sec-0074"> <h5 class="title">Medium‐term health outcomes</h5> <p>None of the studies report medium‐term health outcomes such as reproductive health effects (infertility or miscarriage). </p> </section> <section id="CD012860-sec-0075"> <h5 class="title">Long‐term health outcomes</h5> <p>None of the studies report long‐term health outcomes such as development of any type of cancer. </p> </section> </section> <section id="CD012860-sec-0076"> <h4 class="title">Secondary outcomes</h4> <section id="CD012860-sec-0077"> <h5 class="title">Adverse events</h5> <p>None of the studies report adverse events.</p> </section> <section id="CD012860-sec-0078"> <h5 class="title">Potential cost savings due to reuse of multi‐dose vials</h5> <p>Five studies report on cost savings for drugs or the devices used for administration or both (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>). None of the studies included personnel costs (i.e. the time spent by healthcare professionals on preparation or administration) while calculating the overall costs. Four studies are uncontrolled before‐after studies conducted in a single hospital (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>), and one is an uncontrolled before‐after study conducted in two hospitals (<a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>). Only three studies included the costs of CSTD in the calculation of cost differences (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>). The remaining two studies did not (<a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>). The cost savings due to CSTD are based on the potential of CSTD to maintain drug sterility for a longer period of time. However, only one study included the costs based on actual drug consumption (<a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>); since this study also included the costs of CSTD, these cost savings are actual cost savings. Two studies calculated the actual drugs costs in CSTD group but calculated the potential cost savings based on the number of drug vials that would have been used if CSTD were not used (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>; <a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>). The remaining two studies simulated cost savings based on the drug remaining in the vials (<a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>). Sufficient data for meta‐analysis were available for only one study (<a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a>). For these two reasons (variability in the calculation of costs and the lack of sufficient data to perform the meta‐analysis), we have tabulated the data in <a href="#CD012860-tbl-0003">Table 1</a>, where we report the annual cost savings both as originally reported and after conversion to 2017 USD using the PPP conversion rates and GDP deflators reported in the October 2017 version of the World Economic Outlook Database. </p> <div class="table" id="CD012860-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Potential cost savings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of hospitals</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Device used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method of calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost difference in original currency<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost difference in USD 2017 equivalent<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs of drugs and CSTD used during the period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2015) MYR +148,632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD +221,818</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs for CSTD, actual costs for drug use in CSTD group and hypothetical calculation of drugs necessary if CSTD was not used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2012) USD −596,491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −642,656</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tevadaptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simulation costs based on potential drug left behind in the vial; costs of CSTD were not included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2014) EUR −70,913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −61,202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal/Tevadaptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs of drugs and CSTD used during the period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2006) EUR +160,680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD +155,144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simulation costs based on potential drug left behind in the vial; costs of CSTD were not included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2014) EUR −22,064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −23,370</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CSTD</b>: closed‐system transfer device.<br/> <sup>a</sup>Negative sign indicates cost savings and positive sign indicates increased costs due to the use of CSTD. </p> </div> </div> <p>As noted in <a href="#CD012860-tbl-0003">Table 1</a>, there is significant variability between the studies in terms of whether the use of CSTD results in cost savings (the point estimates of the average potential cost savings range between (2017) USD −642,656 and (2017) USD +221,818). Therefore, we cannot reach any conclusion on whether the use of CSTD in general or a particular type of CSTD results in cost savings. However, the study that reported actual cost savings reported higher costs in the CSTD group than the control group (<a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>). The quality of evidence is very low for this outcome because of the serious risk of bias in all the studies (downgraded by one level) and the significant variability of the results between the studies both in magnitude and direction (downgraded by two levels). </p> </section> </section> <section id="CD012860-sec-0079"> <h4 class="title">Subgroup analysis</h4> <p>We will perform the following subgroup analyses given sufficient data in future updates of this review; the reasons for not performing these in this review are stated below. </p> <p> <ul id="CD012860-list-0012"> <li> <p>Study design (CBA studies versus other non‐randomised study designs): there are no CBA studies. </p> </li> <li> <p>Study design (individual versus cluster unit of analysis): all studies are cluster studies. </p> </li> <li> <p>Professional role (pharmacy technician versus chemotherapy nurse versus other healthcare staff): no separate data were reported for different professional roles in the two studies that included nurses. </p> </li> <li> <p>Duration of possible exposure: the range of exposure to hazardous drugs is from two weeks to seven months in the studies that reported the presence of hazardous drugs in urine and the duration of exposure. Thus, all the studies included participants who had short‐term exposure to hazardous drugs and short‐term follow‐up. </p> </li> <li> <p>Control (safe handling following UK HSE standards): none of the studies took place in the UK, and none of the studies report whether they followed UK HSE standards. </p> </li> </ul> </p> </section> <section id="CD012860-sec-0080"> <h4 class="title">Reporting bias</h4> <p>There was is evidence of reporting bias or small study effects for the following outcomes measured in at least five studies either by visualisation or by Egger's test (<a href="#CD012860-fig-0003">Figure 3</a>; <a href="#CD012860-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012860-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.2 Proportion of surfaces contaminated." data-id="CD012860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.2 Proportion of surfaces contaminated. </p> </div> </div> </div> <div class="figure" id="CD012860-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.3 Quantity of surface contamination (pg/cm²)." data-id="CD012860-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.3 Quantity of surface contamination (pg/cm²). </p> </div> </div> </div> <p> <ul id="CD012860-list-0013"> <li> <p>Proportion of surfaces contaminated</p> </li> </ul> <ul class="plain" id="CD012860-list-0014"> <li> <ul id="CD012860-list-0015"> <li> <p>Ifosfamide (pharmacy areas): P = 0.929</p> </li> <li> <p>Methotrexate (pharmacy areas): P = 0.768</p> </li> <li> <p>Cyclophosphamide (patient‐care areas): P = 0.454</p> </li> <li> <p>Ifosfamide (patient‐care areas): P = 0.582</p> </li> <li> <p>Methotrexate (patient‐care areas): P = 0.438</p> </li> </ul> </li> </ul> <ul id="CD012860-list-0016"> <li> <p>Quantity of surface contamination</p> <ul id="CD012860-list-0017"> <li> <p>Cyclophosphamide (pharmacy areas): P = 0.662</p> </li> <li> <p>Ifosfamide (pharmacy areas): P = 0.509</p> </li> <li> <p>Methotrexate (pharmacy areas): P = 0.479</p> </li> <li> <p>Ifosfamide (patient‐care areas): P = 0.391</p> </li> <li> <p>Methotrexate (patient‐care areas): P = 0.956</p> </li> </ul> </li> </ul> </p> <p>The only exceptions for this are for differences in the proportion of surfaces contaminated with cyclophosphamide and quantity of cyclophosphamide in patient‐care areas, which are statistically significant (P = 0.026 and P = 0.002). This is because the point estimate of the difference between CSTD and control group is less in the studies with the least standard error (i.e. the studies that contributed more to the analysis) compared to the other studies (which contributed less to the meta‐analysis), indicating potential small‐study effects. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012860-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012860-sec-0081"></div> <section id="CD012860-sec-0082"> <h3 class="title" id="CD012860-sec-0082">Summary of main results</h3> <p>In this systematic review, we included 24 observational studies comparing CSTD plus safe handling versus safe handling alone. There are no randomised controlled trials on this topic. Twenty‐two studies report one or more outcomes for this review. However, the only outcomes reported in these 22 studies are exposure, surface contamination, and potential cost savings. None of the studies report important health outcomes relevant for healthcare staff exposed to infusional hazard drugs such as reduction in skin rashes, infertility, miscarriage, or the development of any type of cancer. </p> <p>In terms of exposure, evidence of differences between CSTD plus safe handling versus safe handling alone is too uncertain for drawing conclusions. Decreased exposure, as defined by the presence of one or more hazardous drugs within the body (established via e.g. urine testing) or in the immediate vicinity (established via surface sampling), can result in beneficial short‐term or long‐term health outcomes as exposure to hazardous drugs is probably associated with an increased risk of cancer, decreased fertility, congenital abnormalities, miscarriages, stillbirths, and low birthweight (<a href="./references#CD012860-bbs2-0096" title="ConnorTH , LawsonCC , PolovichM , McDiarmidMA . Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidence. Journal of Occupational and Environmental Medicine2014;56(9):901‐10. ">Connor 2014</a>; <a href="./references#CD012860-bbs2-0113" title="Health and Safety Executive. Safe handling of cytotoxic drugs in the workplace, 2017. www.hse.gov.uk/healthservices/safe‐use‐cytotoxic‐drugs.htm (accessed 7 June 2017). ">HSE 2017</a>; <a href="./references#CD012860-bbs2-0126" title="National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings, 2004. www.cdc.gov/niosh/docs/2004‐165/pdfs/2004‐165.pdf (accessed 7 June 2017). ">NIOSH 2004</a>). </p> <p>There was a statistically significant reduction in the proportion of samples that were contaminated with 5‐fluorouracil (1/24 comparisons of proportion of surfaces contaminated in pharmacy or patient‐care areas) and in the quantity of cyclophosphamide and epirubicin contamination in the CSTD plus safe handling group versus safe handling alone in pharmacy areas (2/15 comparisons of quantity of contamination in pharmacy or patient‐care areas). However, the quality of the evidence of differences in proportion of surfaces contaminated or quantity of surface contamination in pharmacy areas is too low to make a conclusion. Further, the quality of the evidence of differences in the proportion of surfaces contaminated or the quantity of surface contamination in patient areas is also too low to be certain about the presence or absence of a difference. </p> <p>With regards to cyclophosphamide and epirubicin, the surface contamination in pharmacy areas is about 50 pg/cm² and 110 pg/cm² less in the intervention group than in the control. There are multiple issues with this small difference. Firstly, the difference in quantity of contamination was found only for two drugs in the pharmacy area (and did not extend to patient‐care areas or other drugs), that is, the healthcare staff are still exposed to cyclophosphamide or epirubicin in other areas and other hazardous drugs in pharmacy and patient‐care areas. Moreover, by design, CSTDs do not protect healthcare staff from hazardous orally administered drugs. Therefore, the healthcare staff may be exposed to hazardous oral drugs, which can lead to the same ill effects of infusional hazardous drugs. However, hazardous oral drugs were not typically reported in the studies comparing CSTD plus safe handling versus safe handling alone, making it difficult to assess the potential effect of reducing some specific infusional hazardous drugs. Because of the many hazardous drugs to which healthcare professionals are exposed, any assessment of surface contamination and exposure by measuring a limited number of hazardous drugs can only be an estimation of the overall exposure (<a href="./references#CD012860-bbs2-0095" title="ConnorTH . Hazardous anticancer drugs in health care: environmental exposure assessment. Annals of the New York Academy of Sciences2006;1076:615‐23. ">Connor 2006</a>). A correlation between two outcomes does not make one outcome a good surrogate of another (<a href="./references#CD012860-bbs2-0090" title="BucherHC , GuyattGH , CookDJ , HolbrookA , McAlisterFA . Users' guides to the medical literature: Xix. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence‐based medicine working group. JAMA1999;282(8):771‐8. ">Bucher 1999</a>; <a href="./references#CD012860-bbs2-0103" title="FlemingTR , DeMetsDL . Surrogate end points in clinical trials: are we being misled?. Annals of Internal Medicine1996;125(7):605‐13. ">Fleming 1996</a>; <a href="./references#CD012860-bbs2-0118" title="KimC , PrasadV . Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Internal Medicine2015;175(12):1992‐4. ">Kim 2015</a>; <a href="./references#CD012860-bbs2-0132" title="PrenticeRL . Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine1989;8(4):431‐40. ">Prentice 1989</a>; <a href="./references#CD012860-bbs2-0138" title="RuppT , ZuckermanD . Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints. JAMA Internal Medicine2017;177(2):276‐7. ">Rupp 2017a</a>; <a href="./references#CD012860-bbs2-0146" title="YudkinJS , LipskaKJ , MontoriVM . The idolatry of the surrogate. BMJ2011;343:d7995. ">Yudkin 2011</a>). A reduction in the surface contamination by CSTD should result in decreased exposure or increased short or long‐term health outcomes for it to be called a good surrogate outcome. To summarise, the clinical relevance of this small reduction in the quantity of cyclophosphamide or epirubicin in terms of reducing overall exposure and improving short‐term or long‐term health outcomes is not known. </p> <p>With regards to 5‐fluorouracil, the evidence is too uncertain to conclude there is a reduction in quantity of 5‐fluorouracil, though we note a reduction in the proportion of surfaces contaminated with 5‐fluorouracil.There are several possible explanations for this. One possibility is that there was insufficient power to detect a reduction in quantity of 5‐fluorouracil. Even if this were the case (and there was an actual reduction in 5‐fluorouracil), the same issues arise that did for a reduction in cyclophosphamide: does this reduction decrease overall exposure or does it lead to short or long‐term health outcomes. A second possibility is that despite a reduction in the surfaces contaminated with 5‐fluorouracil, the overall quantity of contamination with 5‐fluorouracil is the same. A third possibility is that the differences may be due to different studies included under the outcome, which may reflect selective outcome reporting, which may in turn indicate that there is actually no reduction in the quantity of 5‐fluorouracil. In the second and third possibilities, it is unknown whether reducing the proportion of surfaces contaminated with 5‐fluorouracil without reducing its overall quantity leads to a decrease in overall exposure or to an improvement in health. </p> <p>All things considered, there is substantial uncertainty in whether the addition of CSTD to safe handling practices decreases exposure or has any reduction in exposure or provides short or long‐term health outcomes in healthcare staff using infusional hazardous drugs. </p> <p>There in significant variability in the potential cost savings. The way that the cost savings were calculated varied significantly between the studies. A meta‐analysis is not possible because of the variability in the methods used in calculating potential cost savings and the lack of sufficient information to perform the meta‐analysis. Only one study includes the costs based on actual drug consumption and costs of CSTD (<a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a>). This study reports higher costs. The other studies simulated cost savings, which is likely to overestimate them. None of the studies include personnel costs (costs involved in preparing the drugs and administration of the drugs) when evaluating the cost savings. Overall, there is great uncertainty in whether CSTD saves any money. Future studies should include the total actual drug costs (based on actual drug consumption rather than potential drug consumption), CSTD costs, and personnel costs (costs involved in preparing the drugs and administration of the drugs). </p> <p>Based on the above observations, there is currently significant uncertainty on whether the routine use of CSTD in addition to safe handling of infusional hazardous drugs leads either to decreased exposure, short‐term or long‐term health outcomes, or financial benefits. </p> </section> <section id="CD012860-sec-0083"> <h3 class="title" id="CD012860-sec-0083">Overall completeness and applicability of evidence</h3> <p>Although we did not restrict the inclusion of studies based on the hospital size, all the studies that provide information on the size of the hospitals included only hospitals with at least 50 beds. Therefore, the evidence is applicable only to such hospitals. Most of the information for this review comes from pharmacy areas; therefore the evidence is applicable only for these areas. However, patient‐care areas are equally important, as healthcare staff are also exposed to residual hazardous drugs in these settings. Again, if studies use surrogate measures such as surface contamination to estimate the potential short‐term or long‐term health outcome of CSTD, they should measure surface contamination in patient‐care areas in order to provide a reasonable estimate of the health outcomes of using CSTD. The healthcare professionals in the studies that provide data were mostly pharmacists or pharmacy technicians. Therefore, the evidence is mainly applicable for pharmacists and pharmacy technicians. Most of the studies that provide information for this review evaluated the use of PhaSeal; therefore the findings are mostly applicable to PhaSeal. </p> </section> <section id="CD012860-sec-0084"> <h3 class="title" id="CD012860-sec-0084">Quality of the evidence</h3> <p>The overall quality of evidence is very low. The major reasons for this are as follows.</p> <p><b>Risk of bias</b>: all the studies are at serious risk of bias. The main reasons for this are the use of co‐interventions (for example, additional training of staff in CSTD without the control group receiving the same amount of training in safe handling) and lack of blinded measurement of outcomes. None of the studies report using an independent person (blinded to the groups) for obtaining surface samples. In addition, we assigned a 'no information' label for confounding bias on all the studies due to inadequate information regarding details such as the surfaces being clean prior to the start of the exposure. This is a particularly important problem with uncontrolled before‐after studies since standard cleaning techniques may not be sufficient to get rid of the surface contamination, which might mean that the surfaces might have had several years of exposure to contamination in the 'safe handling alone' group, while those in the 'CSTD group plus safe handling' group are exposed to only a short period of exposure to contamination (a few months typically) because of thorough cleaning prior to start of CSTD. Even when the exposure outcome was measured objectively, such as with a urine test where the levels can be measured using automated equipment, we found the risk of bias to be serious. </p> <p>Future studies should try to address these issues by using appropriate study designs that ensure that the only difference between CSTD and control is the use of CSTD, and that an independent person (blinded to the groups) obtains surface samples. Another major issue is selective reporting bias, as in many instances study authors did not report their results fully. While we acknowledge that it is not mandatory to register observational studies, future studies should publish a protocol prior to conducting the study and report all the results so that it is clear that results are not reported based on the observations. </p> <p><b>Inconsistency</b>: there is no evidence of inconsistency in the results for exposure; however, there is major inconsistency in the methodology and results of potential cost savings by CSTD. In particular, we noted major differences in the results between studies that used actual cost savings and simulated cost savings. Future studies should report the actual cost savings rather than simulated cost savings. </p> <p><b>Indirectness of evidence</b>: because of the many hazardous drugs to which healthcare professionals are exposed, any assessment of exposure by measuring a limited number of hazardous drugs can only be an estimation of the overall exposure (<a href="./references#CD012860-bbs2-0095" title="ConnorTH . Hazardous anticancer drugs in health care: environmental exposure assessment. Annals of the New York Academy of Sciences2006;1076:615‐23. ">Connor 2006</a>). In addition, surface contamination can be considered a surrogate for exposure since there is an association between the two variables (<a href="./references#CD012860-bbs2-0095" title="ConnorTH . Hazardous anticancer drugs in health care: environmental exposure assessment. Annals of the New York Academy of Sciences2006;1076:615‐23. ">Connor 2006</a>). </p> <p><b>Imprecision</b>: as shown in the sample size calculations below, the sample size included in this review is too small to detect a difference in urinary exposure. In the absence of information on how much difference in proportion of samples contaminated or in quantity of contamination is clinically beneficial, it was not easy to assess whether the overall sample size was sufficient to detect differences between CSTD and control for surface contamination. </p> <p><b>Publication bias</b>: visualisation of funnel plots and Egger's test did not reveal any publication bias for most of the outcomes in which at least five studies were included. Registration of studies prior to conducting them allows better assessment of both selective reporting and publication bias. </p> </section> <section id="CD012860-sec-0085"> <h3 class="title" id="CD012860-sec-0085">Potential biases in the review process</h3> <p>We followed the protocol we formulated before we started conducting this Cochrane systematic review (<a href="./references#CD012860-bbs2-0148" title="GurusamyKS , BestLMJ , TanguayC , LennanE , KorvaM , BussièresJF . Closed‐system drug‐transfer devices in addition to safe handling of hazardous drugs versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD012860] ">Gurusamy 2017</a>). The only major deviation is the sensitivity analysis using different intracluster correlation coefficients (ICCs). However, we performed this only to assess the reason for the differences in the conclusions reached by us and a number the study authors; in particular, we did not use these post hoc sensitivity analyses to make any inferences about the effect of CSTD. </p> <p>While we have minimised the errors in study selection and data extraction by independent, duplicate performance of these processes, we may have missed studies that do not mention CSTD in the title or abstract. It is impractical to review the full text of all references (we identified 7321 unique references using our search strategy). In this regard, we followed our protocol of screening the title and abstract and obtaining full texts for references considered relevant based on the full text. Besides, these studies (which do not mention CSTD in the title or abstract) are likely to show no evidence of benefit of CSTD (the probable reason for not mentioning CSTD in the title or abstract); therefore, our conclusions are unlikely to change. </p> <p>None of the studies reported an ICC. Therefore, we used the value of 0.10 decided a priori based on studies about implementation research (<a href="./references#CD012860-bbs2-0091" title="CampbellMK , MollisonJ , GrimshawJM . Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Statistics in Medicine2001;20(3):391‐9. ">Campbell 2001</a>). The results were robust in a sensitivity analysis using 0.05 for the ICC (i.e. half the correlation noted in similar studies) for most analyses; therefore, our conclusions would probably not change even if the studies had reported the intracluster correlation. However, we recommend that study authors report intracluster correlations in the future to enable accurate estimation of their results. </p> </section> <section id="CD012860-sec-0086"> <h3 class="title" id="CD012860-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>This is the first systematic review on the topic. We disagree with the study authors who concluded that routine CSTD use is beneficial (<a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a>; <a href="./references#CD012860-bbs2-0007" title="HamaT . Issues occurring in preparation of anticancer agents. Annals of Oncology2012;23(Suppl 11):xi68. ">Hama 2012</a>; <a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a>; <a href="./references#CD012860-bbs2-0011" title="MiyakeT , IwamotoT , TanimuraM , OkudaM . Impact of closed‐system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital. Springerplus2013;2:273. ">Miyake 2013</a>; <a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a>; <a href="./references#CD012860-bbs2-0016" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , ConnorTH , JorgensonJA , TylerTG . Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2011;17(1):39‐48. ">Sessink 2011</a>; <a href="./references#CD012860-bbs2-0017" title="SessinkPJ . Additional information on study methods and data related to study. Sessink PJAugust 2017. SessinkPJ , TrahanJ , CoyneJW . Reduction in surface contamination with cyclophosphamide in 30 us hospital pharmacies following implementation of a closed‐system drug transfer device. Hospital Pharmacy2013;48(3):204‐12. ">Sessink 2013</a>; <a href="./references#CD012860-bbs2-0018" title="SiderovJ , KirsaS , McLauchlanR . Reducing workplace cytotoxic surface contamination using a closed‐system drug transfer device. Journal of Oncology Pharmacy Practice2010;16(1):19‐25. ">Siderov 2010</a>; <a href="./references#CD012860-bbs2-0019" title="SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Effectiveness of a closed‐system transfer device in reducing surface contamination in a new antineoplastic drug‐compounding unit: a prospective, controlled, parallel study. PLOS ONE2016;11(7):e0159052. SimonN , VasseurM , PinturaudM , SoichotM , RichevalC , HumbertL , et al. Using a closed‐system transfer device leads to better control of occupational exposure in routine practice. European Journal of Hospital Pharmacy2015;22(Suppl 1):A122‐3. ">Simon 2016</a>; <a href="./references#CD012860-bbs2-0022" title="WickC , SlawsonMH , JorgensonJA , TylerLS . Using a closed‐system protective device to reduce personnel exposure to antineoplastic agents. American Journal of Health‐System Pharmacy2003;60(22):2314‐20. ">Wick 2003</a>; <a href="./references#CD012860-bbs2-0024" title="YoshidaJ , KodaS , NishidaS , YoshidaT , MiyajimaK , KumagaiS . Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan. Journal of Oncology Pharmacy Practice2011;17(1):29‐38. ">Yoshida 2011</a>). Ignoring the design effect by not adjusting the effect estimates for intracluster correlation can lead to an underestimation of random errors (<a href="./references#CD012860-bbs2-0117" title="KillipS , MahfoudZ , PearceK . What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Annals of Family Medicine2004;2(3):204‐8. ">Killip 2004</a>); consequently this could lead to erroneous conclusions. Many study authors concluded that CSDTs decrease contamination or exposure in contrast to our conclusion that this is uncertain. The reason for this discrepancy is that the study authors appear to have ignored the clustering of participants and the risk of bias in their studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012860-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram. CSTD: closed‐system transfer device" data-id="CD012860-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram. <b>CSTD</b>: closed‐system transfer device </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green +: Low risk of bias. Yellow ?: Moderate risk of bias or 'No information'. Red ‐: Serious or critical risk of bias." data-id="CD012860-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Green +: Low risk of bias. Yellow ?: Moderate risk of bias or 'No information'. Red ‐: Serious or critical risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.2 Proportion of surfaces contaminated." data-id="CD012860-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.2 Proportion of surfaces contaminated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.3 Quantity of surface contamination (pg/cm²)." data-id="CD012860-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Closed‐system transfer device plus safe handling versus safe handling alone, outcome: 1.3 Quantity of surface contamination (pg/cm²). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 1 Urine tests for exposure." data-id="CD012860-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 1 Urine tests for exposure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 2 Proportion of surfaces contaminated." data-id="CD012860-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 2 Proportion of surfaces contaminated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 3 Quantity of surface contamination (pg/cm²)." data-id="CD012860-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Closed‐system transfer device plus safe handling versus safe handling alone, Outcome 3 Quantity of surface contamination (pg/cm²). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 1 Urine tests for exposure (PhaSeal only)." data-id="CD012860-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 1 Urine tests for exposure (PhaSeal only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 2 Proportion of surfaces contaminated with cyclophosphamide in pharmacy areas: stratified by study design." data-id="CD012860-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 2 Proportion of surfaces contaminated with cyclophosphamide in pharmacy areas: stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 3 Proportion of surfaces contaminated with ifosfamide in pharmacy areas: stratified by study design." data-id="CD012860-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 3 Proportion of surfaces contaminated with ifosfamide in pharmacy areas: stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 4 Proportion of surfaces contaminated with methotrexate in pharmacy areas: stratified by study design." data-id="CD012860-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 4 Proportion of surfaces contaminated with methotrexate in pharmacy areas: stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 5 Proportion of surfaces contaminated with 5‐fluorouracil in pharmacy areas: stratified by study design." data-id="CD012860-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 5 Proportion of surfaces contaminated with 5‐fluorouracil in pharmacy areas: stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 6 Proportion of surfaces contaminated (PhaSeal only)." data-id="CD012860-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 6 Proportion of surfaces contaminated (PhaSeal only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 7 Proportion of surfaces contaminated (Tevadaptor only)." data-id="CD012860-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 7 Proportion of surfaces contaminated (Tevadaptor only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 8 Quantity of surface contamination with cyclophosphamide in pharmacy areas (pg/cm²): stratified by study design." data-id="CD012860-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 8 Quantity of surface contamination with cyclophosphamide in pharmacy areas (pg/cm²): stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 9 Quantity of surface contamination with ifosfamide in pharmacy areas (pg/cm²): stratified by study design." data-id="CD012860-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 9 Quantity of surface contamination with ifosfamide in pharmacy areas (pg/cm²): stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 10 Quantity of surface contamination with methotrexate in pharmacy areas (pg/cm²): stratified by study design." data-id="CD012860-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 10 Quantity of surface contamination with methotrexate in pharmacy areas (pg/cm²): stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 11 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by devices." data-id="CD012860-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 11 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by devices. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 12 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by study design." data-id="CD012860-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 12 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis (based on study design and device), Outcome 13 Quantity of surface contamination (pg/cm²): stratified by devices." data-id="CD012860-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis (based on study design and device), Outcome 13 Quantity of surface contamination (pg/cm²): stratified by devices. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 1 Urine tests for exposure (ICC = 0.05)." data-id="CD012860-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 1 Urine tests for exposure (ICC = 0.05).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 2 Urine tests for exposure (ICC = 0.01)." data-id="CD012860-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 2 Urine tests for exposure (ICC = 0.01).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 3 Urine tests for exposure (ICC = 0.00)." data-id="CD012860-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 3 Urine tests for exposure (ICC = 0.00).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 4 Proportion of surfaces contaminated (ICC = 0.05)." data-id="CD012860-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 4 Proportion of surfaces contaminated (ICC = 0.05). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 5 Proportion of surfaces contaminated (ICC = 0.01)." data-id="CD012860-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 5 Proportion of surfaces contaminated (ICC = 0.01). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 6 Proportion of surfaces contaminated (ICC = 0.00)." data-id="CD012860-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 6 Proportion of surfaces contaminated (ICC = 0.00). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 7 Quantity of surface contamination (pg/cm²) (ICC = 0.05)." data-id="CD012860-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 7 Quantity of surface contamination (pg/cm²) (ICC = 0.05). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 8 Quantity of surface contamination (pg/cm²) (ICC = 0.01)." data-id="CD012860-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 8 Quantity of surface contamination (pg/cm²) (ICC = 0.01). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012860-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/urn:x-wiley:14651858:media:CD012860:CD012860-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_t/tCD012860-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 9 Quantity of surface contamination (pg/cm²) (ICC = 0.00)." data-id="CD012860-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 9 Quantity of surface contamination (pg/cm²) (ICC = 0.00). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/media/CDSR/CD012860/image_n/nCD012860-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012860-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and surface contamination</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Closed‐system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and contamination</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : healthcare staff who handle infusional hazardous drugs<br/> <b>Settings</b> : hospitals<br/> <b>Intervention</b> : closed‐system transfer device plus safe handling<br/> <b>Control</b>: safe handling alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of hospitals<br/> (samples; studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Safe handling alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Closed‐system transfer device plus safe handling</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Exposure (urine tests for exposure)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide alone</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>761 per 1000</b><br/> (422 to 1393) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b><br/> (0.46 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 hospitals</p> <p>(20 participants; 2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide or ifosfamide</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b><br/> (0 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.09</b><br/> (0.00 to 2.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 hospital</p> <p>(14 participants; 1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no participants with exposure in either group.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 hospitals</p> <p>(36 participants; 1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of exposure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report on blood tests or other measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, or micronuclei induction. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surface contamination (proportion of surfaces contaminated)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Pharmacy areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>507 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/> (395 to 512) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b><br/> (0.78 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338 hospitals<br/> (2937 samples; 13 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b><br/> (197 to 317) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/> (0.74 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304 hospitals<br/> (2332 samples; 9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (59 to 124) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.84</b><br/> (0.58 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1781 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>149 per 1000</b><br/> (99 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.63<br/> (0.42 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 hospitals<br/> (1068 samples; 4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cytarabine</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>267 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b><br/> (48 to 762) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b><br/> (0.18 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 hospitals<br/> (780 samples; 2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Gemcitabine</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>322 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>309 per 1000</b><br/> (193 to 496) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b><br/> (0.60 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 hospitals<br/> (780 samples; 2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, multiple drugs</i><sup>ϯ</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the proportion of samples contaminated with 5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, or multiple drugs in pharmacy areas between closed‐system transfer device plus safe handling versus safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irinotecan, docetaxel, paclitaxel, vinorelbine: 83 hospitals<br/> (493 samples; 1 study) </p> <p>Ganciclovir: 1 hospital<br/> (287 samples; 1 study) </p> <p>Epirubicin: 1 hospital (60 samples; 1 study)</p> <p>Multiple drugs: 4 hospitals<br/> (109 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Patient‐care areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>440 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/> (378 to 519) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b><br/> (0.86 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b><br/> (64 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.44</b><br/> (0.91 to 2.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/> (14 to 46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.55 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugs</i><sup>ϯ</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the proportion of samples contaminated with 5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugs in patient‐care areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine: 83 hospitals<br/> (493 samples; 1 study) </p> <p>Multiple drugs: 4 hospitals<br/> (33 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Surface contamination (quantity of surface contamination (pg/cm²))</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Pharmacy areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i><sup>‡</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the control group is<br/> <b>124.30 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the intervention group is <b>49.34 pg/cm² lower</b><br/> (84.11 lower to 14.56 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −49.34 pg/cm²</b> </p> <p>(−84.11 to −14.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282 hospitals<br/> (1793 samples; 7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the control group is<br/> <b>10.8 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the intervention group is <b>0.32 pg/cm² lower</b><br/> (6.58 lower to 5.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −0.32 pg/cm²</b> </p> <p>(−6.58 to 5.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1749 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the control group is<br/> <b>18.23 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the intervention group is <b>3.09 pg/cm² lower</b><br/> (13.80 lower to 7.61 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −3.09 pg/cm²</b> </p> <p>(−13.80 to 7.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 hospitals<br/> (1749 samples; 6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 5‐fluorouracil in the control group is<br/> 740 pg/cm² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 5‐fluorouracil in the intervention group is <b>231.62 pg/cm² higher</b> (460.52 lower to 923.76 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 231.62</b> </p> <p>(−460.52 to 923.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 hospitals<br/> (602 samples; 3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean epirubicin in the control group is<br/> 110 pg/cm² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean 5‐fluorouracil in the intervention group is <b>110.00 pg/cm² lower</b> (112.93 lower to 107.07 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD −110.00</b> (−112.93 to −107.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 hospital<br/> (60 samples; 1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cytarabine, gemcitabine, and irinotecan</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the amount of cytarabine, gemcitabine, and irinotecan in pharmacy areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 hospitals<br/> (493 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b><i>Patient‐care areas</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Cyclophosphamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the control groups is<br/> <b>168 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cyclophosphamide in the intervention group is<br/> <b>13.34 pg/cm² lower</b><br/> (36.01 lower to 9.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD −13.34 pg/cm²</b> </p> <p>(−36.01 to 9.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Ifosfamide</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the control group is<br/> <b>4.59 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean ifosfamide in the intervention group is<br/> <b>3.59 pg/cm² higher</b><br/> (3.45 lower to 10.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.59 pg/cm²</b> </p> <p>(−3.45 to 10.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>Methotrexate</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the control groups is<br/> <b>1.42 pg/cm²</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean methotrexate in the intervention group is <b>0.10 pg/cm² higher</b><br/> (0.57 lower to 0.78 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.10 pg/cm²</b> </p> <p>(−0.57 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 hospitals<br/> (1535 samples; 5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>5‐fluorouracil, cytarabine, gemcitabine, and irinotecan</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There is no evidence of difference in the amount of 5‐fluorouracil, cytarabine, gemcitabine, and irinotecan in patient‐care areas between closed‐system transfer device plus safe handling and safe handling alone </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 hospitals<br/> (460 samples; 1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other measures of contamination</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report on atmospheric contamination.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>MD</b> : mean difference; <b>RR</b>: risk ratio </p> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <sup>ϯ</sup>Report contains multiple drugs with no outcome information on individual drugs.<br/> <sup>‡</sup>In addition, one interrupted time‐series study (three hospitals; 342 samples) provided data on the quantity of contamination with cyclophosphamide from surface samples in pharmacy areas during three phases, initial phase of no CSTD, followed by CSTD, and then by no CSTD, each phase lasting three weeks (<a href="./references#CD012860-bbs2-0008" title="HarrisonBR , PetersBG , BingMR . Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed‐system drug transfer device versus standard preparation techniques. American Journal of Health‐System Pharmacy2006;63(18):1736‐44. ">Harrison 2006</a>). The authors took biweekly measurements in all three phases. Between the first two phases, the change in the slope between pre‐CSTD and CSTD was 3.9439 pg/cm² (95% CI 1.2303 to 6.6576; P = 0.01). Between the second and third phases, the slope and level were expected to rise again but the change in the slope between CSTD and post‐CSTD withdrawal was −1.9331 pg/cm², 95% CI −5.126 to 1.2598 (P = 0.200) and the level was 14.167 pg/cm² (SD = 10.619). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The study or studies was or were at serious risk of bias (downgraded one level for risk of bias).<br/> <sup>b</sup>The confidence intervals were wide (downgraded one level for imprecision).<br/> <sup>c</sup>The sample size was small (downgraded one level for imprecision).<br/> <sup>d</sup>This is a surrogate measure of health benefit (downgraded one level for indirectness).<br/> <sup>e</sup>There was possible evidence of publication bias (Egger's test P value &lt; 0.05) (downgraded one level for publication bias).<br/> <sup>f</sup>There is no evidence that this small difference in levels of cyclophosphamide leads to decreased exposure or tangible health benefits (downgraded one level for imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and surface contamination</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012860-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Closed‐system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population</b> : healthcare staff who handle infusional hazardous drugs<br/> <b>Settings</b> : hospitals<br/> <b>Intervention</b> : closed‐system transfer device plus safe handling<br/> <b>Control</b>: safe handling alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of hospitals<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Safe handling alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Closed‐system transfer device plus safe handling</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report health outcomes such as skin rashes, reproductive health effects (infertility or miscarriage), or development of any type of cancer. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>None of the studies report this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Potential cost savings</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The studies used different methods of calculating the costs and reported results in formats that could not be pooled via meta‐analysis. There is significant variability between the studies in terms of whether the use of CSTD results in cost savings (the point estimates of the average potential cost savings ranged between (2017) US D−642,656 and (2017) USD +221,818*. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 hospitals<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*Negative sign indicates cost savings and positive sign indicate increased costs due to the use of closed‐system transfer device. </p> <p><b>CI</b> : confidence interval; <b>CSTD</b>: closed‐system transfer device. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The studies are at serious risk of bias (downgraded one level for risk of bias).<br/> <sup>b</sup>There is very serious inconsistency in magnitude and direction of effect (downgraded two levels for inconsistency). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012860-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Potential cost savings</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of hospitals</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Device used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Method of calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost difference in original currency<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost difference in USD 2017 equivalent<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0002" title="ChanH , HassaliMA . Additional information on study methods and data related to study. Hassali MAAugust 2017. ChanH , LimCJ , HassaliMA , SaleemF . Closed‐system transfer device for preparation of antineoplastic drugs in a Malaysian public hospital: is it truly cost saving?. Value in Health2016;19(7):A860. ChanHK , LimYM . Cost analysis of using a closed‐system transfer device (CSTD) for antineoplastic drug preparation in a Malaysian government‐funded hospital. Asian Pacific Journal of Cancer Prevention2016;17(11):4951‐7. ">Chan 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs of drugs and CSTD used during the period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2015) MYR +148,632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD +221,818</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0004" title="EdwardsM . Cost savings realized by use of a closed‐system transfer device (CSTD) for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(1 Suppl):5. EdwardsM , SolimandoD , GrollmanF , PangJ , PrestonL , JohnsonA , et al. Cost savings realized by use of a closed‐system transfer device for preparation of antineoplastic agents. Journal of the American Pharmacists Association2013;53(5):e153. EdwardsMS . Additional information on study methods and data related to study. Edwards MSAugust 2017. EdwardsMS , SolimandoDA , GrollmanFR , PangJL , ChasickAH , HightmanCM , et al. Cost savings realized by use of the Phaseal closed‐system transfer device for preparation of antineoplastic agents. Journal of Oncology Pharmacy Practice2013;19(4):338‐47. ">Edwards 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs for CSTD, actual costs for drug use in CSTD group and hypothetical calculation of drugs necessary if CSTD was not used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2012) USD −596,491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −642,656</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0010" title="JuhaszA , BatkaG , SzucsA . Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs and Therapy Perspectives2016;32(4):170‐6. ">Juhasz 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tevadaptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simulation costs based on potential drug left behind in the vial; costs of CSTD were not included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2014) EUR −70,913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −61,202</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0012" title="MullotH , BlondeelS , EscalupL , NegellenS , ChenaillerC , PelloquinA , et al. Intérêt et faisabilité des systèmes Tevadaptor et Phaseal® dans une unité centralisée de préparation des anticancéreux. Le Pharmacien Hospitalier2008;43(175):189‐99. ">Mullot 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal/Tevadaptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actual costs of drugs and CSTD used during the period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2006) EUR +160,680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD +155,144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012860-bbs2-0013" title="OzyamanA , BirliE , SarikayaMA . Drug savings realised by use of a right closed system transfer device in the preparation of antineoplastic drugs. European Journal of Hospital Pharmacy2016;23:A202. ">Ozyaman 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phaseal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simulation costs based on potential drug left behind in the vial; costs of CSTD were not included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2014) EUR −22,064</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(2017) USD −23,370</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>CSTD</b>: closed‐system transfer device.<br/> <sup>a</sup>Negative sign indicates cost savings and positive sign indicates increased costs due to the use of CSTD. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Potential cost savings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/full#CD012860-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012860-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urine tests for exposure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cyclophoshamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Cyclophosphamide or ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of surfaces contaminated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.58, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.42, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.18, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.60, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.10, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Docetaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Paclitaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.04, 9.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Vinorelbine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.16, 18.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Ganciclovir (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 27.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Multiple drugs (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.43, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.86, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.91, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.55, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.53, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.01, 24.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.55, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.03, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21 Docetaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.01, 24.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22 Paclitaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.01, 24.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23 Vinorelbine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24 Multiple drugs (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.69, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Quantity of surface contamination (pg/cm²) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.34 [‐84.11, ‐14.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐6.58, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.09 [‐13.80, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>231.62 [‐460.52, 923.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐15.67, 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.7 [‐102.43, 37.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.27 [‐56.89, 20.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐110.0 [‐112.93, ‐107.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.34 [‐36.01, 9.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.59 [‐3.45, 10.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.57, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.9 [‐141.51, 53.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.79, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.77, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.15, 0.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Closed‐system transfer device plus safe handling versus safe handling alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012860-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (based on study design and device)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urine tests for exposure (PhaSeal only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cyclophoshamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Cyclophosphamide or ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of surfaces contaminated with cyclophosphamide in pharmacy areas: stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of surfaces contaminated with ifosfamide in pharmacy areas: stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.65, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of surfaces contaminated with methotrexate in pharmacy areas: stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.58, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.01, 777.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion of surfaces contaminated with 5‐fluorouracil in pharmacy areas: stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.42, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.38, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proportion of surfaces contaminated (PhaSeal only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.01, 777.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.36, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.08, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.33, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Ganciclovir (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 27.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proportion of surfaces contaminated (Tevadaptor only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 6.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quantity of surface contamination with cyclophosphamide in pharmacy areas (pg/cm²): stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.34 [‐84.11, ‐14.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐255.35 [‐1144.66, 633.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.02 [‐83.82, ‐14.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quantity of surface contamination with ifosfamide in pharmacy areas (pg/cm²): stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐6.58, 5.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.59 [‐26.75, 21.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐8.58, 7.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quantity of surface contamination with methotrexate in pharmacy areas (pg/cm²): stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.09 [‐13.80, 7.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.34 [‐34.01, 54.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.92 [‐14.96, 7.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by devices <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 5‐fluorouracil (pharmacy areas; SpikeSwan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14300.0 [‐47951.46, 76551.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 5‐fluorouracil (pharmacy areas; Tevadaptor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐118.00 [‐2746.04, 2506.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Quantity of surface contamination with 5‐fluorouracil in pharmacy areas (pg/cm²): stratified by study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>231.62 [‐460.52, 923.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Uncontrolled before‐after studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐118.00 [‐2746.04, 2506.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Cross‐sectional studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>257.87 [‐459.65, 975.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Quantity of surface contamination (pg/cm²): stratified by devices <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Cyclophosphamide (pharmacy areas; PhaSeal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐255.35 [‐1144.66, 633.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Ifosfamide (pharmacy areas; PhaSeal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.59 [‐26.75, 21.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Methotrexate (pharmacy areas; PhaSeal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.34 [‐34.01, 54.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 5‐fluorouracil (pharmacy areas; SpikeSwan)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14300.0 [‐47951.46, 76551.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 5‐fluorouracil (pharmacy areas; Tevadaptor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐118.00 [‐2746.04, 2506.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis (based on study design and device)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012860-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Urine tests for exposure (ICC = 0.05) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cyclophoshamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Cyclophosphamide or ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.00, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Urine tests for exposure (ICC = 0.01) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cyclophoshamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Cyclophosphamide or ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Urine tests for exposure (ICC = 0.00) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cyclophoshamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.43, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Cyclophosphamide or ifosfamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Cyclophosphamide, ifosfamide, or gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of surfaces contaminated (ICC = 0.05) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.60, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.42, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.17, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.64, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.11, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Docetaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Paclitaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.05, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Vinorelbine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.20, 15.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Ganciclovir (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13 Multiple drugs (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.49, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.91, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.57, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.17 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.57, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 18.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.58, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.04, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.21 Docetaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 18.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.22 Paclitaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 18.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.23 Vinorelbine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.24 Multiple drugs (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.79, 7.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proportion of surfaces contaminated (ICC = 0.01) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.73, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.33, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.17, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Docetaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Paclitaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.06, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Vinorelbine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.23, 12.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Ganciclovir (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 Multiple drugs (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.57, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.85, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.91, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.60, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.59, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 13.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.61, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.20 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.05, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.21 Docetaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 13.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.22 Paclitaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 13.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.23 Vinorelbine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.24 Multiple drugs (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.89, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proportion of surfaces contaminated (ICC = 0.00) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.59, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.63, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.16, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.13, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Docetaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Paclitaxel (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.06, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Vinorelbine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.24, 12.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Ganciclovir (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13 Multiple drugs (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.60, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.85, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.91, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.16 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.61, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.17 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.60, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.18 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 14.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.19 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.62, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.20 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.05, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.21 Docetaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 14.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.22 Paclitaxel (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.02, 14.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.23 Vinorelbine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.24 Multiple drugs (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.92, 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Quantity of surface contamination (pg/cm²) (ICC = 0.05) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.47 [‐81.21, ‐17.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐7.63, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.78 [‐12.45, 6.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>224.25 [‐400.98, 849.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐14.37, 13.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.7 [‐96.40, 31.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.27 [‐53.55, 17.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐110.0 [‐112.32, ‐107.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.44 [‐90.78, 29.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.59 [‐2.88, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.51, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.9 [‐133.57, 45.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.74, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.59, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.15 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.14, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quantity of surface contamination (pg/cm²) (ICC = 0.01) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.85 [‐78.93, ‐20.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.29 [‐7.89, 5.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.93 [‐10.50, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>207.62 [‐351.04, 766.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐13.23, 12.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.7 [‐91.14, 25.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.27 [‐50.63, 14.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐110.0 [‐111.68, ‐108.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐49.62 [‐133.49, 34.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.59 [‐2.39, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.11 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.81, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.12 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.9 [‐126.66, 38.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.13 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.2 [‐0.70, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.14 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.43, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.15 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quantity of surface contamination (pg/cm²) (ICC = 0.00) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Cyclophosphamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐50.15 [‐78.51, ‐21.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Ifosfamide (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.36 [‐7.81, 5.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Methotrexate (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.32 [‐9.47, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 5‐fluorouracil (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>198.18 [‐338.80, 735.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Cytarabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐12.93, 11.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Gemcitabine (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.7 [‐89.74, 24.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Irinotecan (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.27 [‐49.86, 13.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Epirubicin (pharmacy areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐110.0 [‐111.48, ‐108.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.9 Cyclophosphamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐53.61 [‐141.33, 34.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.10 Ifosfamide (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [‐2.27, 9.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.11 Methotrexate (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐1.02, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.12 5‐fluorouracil (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐43.9 [‐124.84, 37.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.13 Cytarabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.2 [‐0.69, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.14 Gemcitabine (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐1.39, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.15 Irinotecan (patient‐care areas)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012860.pub2/references#CD012860-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012860.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012860-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012860-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012860-note-0007">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012860\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012860\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012860\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012860\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012860\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012860.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012860.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012860.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012860.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012860.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715376318"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012860.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715376326"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012860.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d85922c59f446',t:'MTc0MDcxNTM3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 